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Abstract. 
The regenerative capacities between the peripheral and central nervous systems are 
contrasting; with axons in the peripheral nervous system being able to regenerate, unlike 
those in the central nervous system (CNS). Upon injury, the CNS responds by releasing 
myelin breakdown products, which are inhibitory to axon regrowth, and the formation of 
the glial scar which forms a physical barrier to regeneration. Whilst the formation of the 
glial scar takes days or weeks to form, the myelin breakdown products, which include 
myelin associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp) and 
Nogo, exert their inhibitory effects immediately. These products bind to the Nogo 
Receptor (NgR) complex which consists of the Nogo receptor (NgR), p75 neurotrophin 
receptor (p75
NTR
)/ (or an alternative protein known as TROY) and Lingo-1 which work 
together to activate RhoA, resulting in actin depolymerisation and growth cone collapse. 
The specific mechanisms by which this complex exhibits its effects remain unclear, 
particularly as recent unpublished data suggest that specific members of the Amigo family 
of proteins may be critical mediators of the inhibitory signaling pathway in vivo. This 
suggestion prompted us to clone NgR, p75
NTR 
and Amigos 1, 2 and 3 in mammalian 
expression vectors and perform co-immunoprecipitation experiments with these constructs. 
These experiments suggest that Amigo-1 and -3 bind to NgR and/or p75
NTR
 both 
independently or when expressed together. Although the approach was only 
semiquantitative at best, the experiments also suggest that Amigo 2 may bind to NgR and 
p75
NTR
 independently and together, but to a much lesser extent. The results indicate that 
the Amigo family of proteins may form a component of the axon growth inhibitory 
complex, and potentially forming novel therapeutic targets for CNS injury. 
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1. Introduction 
It has long been known that there is a difference in the regenerative capacities between the 
central nervous system (CNS) and peripheral nervous system (PNS). In common with 
most tissues, axons in the PNS are generally able to regenerate successfully after injury, 
whilst those in the CNS exhibit limited regeneration at best. A consequence of this is that 
functional recovery after CNS injury or disease is rare. The biochemical and cellular 
mechanisms underlying these differences are likely to be multifactorial, and are a subject 
of substantial interest because understanding them could lead to new therapeutic 
opportunities to enhance regeneration of axons after tissue injury or in diseases. After 
damage occurs to the CNS it undergoes an injury response which involves a series of 
events evolving over several days and weeks [1]. These include the release of myelin 
breakdown products and the subsequent formation of a glial scar,  two phenomena acting 
to prevent regeneration of damaged axons [2].  Damage to myelin occurs early following 
injury, leading to the local release of inhibitory factors including myelin associated 
glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp) and Nogo. Therefore 
these myelin breakdown products play a critical role in preventing neuronal regeneration 
but currently their mechanisms remain unclear. In contrast to the rapid release of myelin 
derived inhibitors, the glial scar is established over weeks as a meshwork of reactive 
astrocytes, oligodendrocyte precursors, and microglia that may form a physical barrier to 
regeneration [3]. Astrocytes within the glial scar also upregulate the production of several 
extracellular matrix associated inhibitors of regeneration [2] including chondroitin sulphate 
proteoglycans (CSPGs) which are important in the development and maintenance of the 
normal CNS, but are also the main inhibitory molecules to axon regeneration in the glial 
scar [4]. Evidence that CSPGs are inhibitory to axon regeneration comes from research 
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showing that levels of CSPGs are elevated around CNS injuries [1] and that axon 
regeneration stops around the area that these CSPGs accumulate. CSPGs are detected a 
few days after injury to the CNS and remain for several weeks after making the 
environment around the site of injury hostile to axonal survival and growth for a 
considerable period.  
 
It is widely acknowledged that the inhibitory signals transmitted to neurons in the early 
stage of the inhibitory process mediated by myelin breakdown products play a critical role 
in establishing the inhibitory effects of the glial scar and CSPGs. Affecting this early stage 
inhibitory signal provided by the release of these products, prior to the formation of the 
glial scar and CSPGs are released, would be critical to the success of therapeutic 
interventions aimed at promoting CNS regeneration following injury.  
 
1.1. MAG 
Immediately following CNS injury which causes damage to myelin, debris containing 
inhibitory proteins is released. These proteins are removed very slowly from the site of 
injury due to the low phagocytic activity in this area. These myelin derived inhibitory 
proteins include MAG, OMgp and Nogo. Myelin associated glycoprotein (MAG) is 
produced by oligodendrocytes, and has roles in axon stability, controlling axon 
cytoarchitecture and regulating axon outgrowth [5]. MAG is a sialic acid binding- SIGLEC 
(sialic acid- dependent immunoglobulin- like family member lectin) protein [6] which 
binds to gangliosides GD1a and GT1b on nerve cells and axons [5]. MAG has also been 
found to be a ligand for the Nogo receptor (NgR), which it binds to with high affinity. 
MAG seems to have a complex function, inhibiting specific axon growth pathways, also 
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MAG knockout mice only display a limited enhancement of axon regeneration in the CNS. 
So whilst it is clear that MAG has inhibitory roles in axon regeneration in the CNS it is 
also clear that there are other inhibitory proteins present. 
 
1.2. OMgp 
Oligodendrocyte myelin protein (OMgp) is a glycosylphosphatidylinositol (GPI) anchored 
protein present on the surface of oligodendrocytes and myelin surfaces adjacent to axons. 
It was found to be inhibitory to axon regrowth when myelin fractions were tested for 
inhibitory activity [7]. OMgp has been found to cause growth cone collapse in vitro but its 
function in vivo is not yet known [8].  
 
1.3. Nogo 
Early experiments (Caroni et al. 1988, Schwab and Caroni 1988) found that a 250kDa 
protein extracted from myelin was responsible for inhibiting neurite outgrowth; this was 
termed NI-250. An antibody called 1N-1 was raised against this protein which blocked the 
inhibitory activity of this protein which was subsequently named Nogo. 
 
Nogo belongs to the Reticulon (RTN) family of proteins which are a large group of 
membrane-associated proteins present in all eukaryotic organisms [9]. There are four 
different RTN genes with Nogo classified as RTN 4. Additionally, there are 3 isoforms of 
Nogo known as Nogo-A, -B and –C which are generated by alternative promotor  usage 
and/or splicing from a single RTN4 gene [10]. The proteins share a 188 amino acid 
domain in their C terminal regions, known as the reticulon homology domain (RHD) 
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which is highly conserved between RTN protein members [10]. The RHD is composed of 
two membrane spanning hydrophobic stretches [11] which are separated by a 66 residue 
hydophillic segment, a domain conserved throughout the three isoforms of Nogo, whereas 
the amino terminal regions, dervived from alternative RNA splicing events, are not 
structurally related [12]. The topology of Nogo is unusual, with the N terminus and C 
terminus cytosolic and the short 66 amino acid axon inhibitory loop protruding into the 
luminal or extracellular space [13].  
 
Nogo-A is the longest isoform of Nogo and is highly expressed in oligodendrocytes but 
not in Schwann cells [14] ,consistent with finding that Nogo-A is a major CNS myelin 
associated inhibitor. Nogo-B and Nogo-C have not been identified in  myelin-forming 
oligodendrocytes and so most studies to date have focussed on Nogo-A [14]. Expression 
levels are dynamic - , with Nogo-A expression levels increased after trauma [15]. Nogo-A 
is principally expressed in the endoplasmic reticulum, in a finely granulated pattern, with a 
small amount been expressed at the cell surface [12]. So far two regions have been 
identified on this protein that have a negative affect on the regeneration of neurons,  the 
first being common to all three isoforms - an extracelular 66 amino acid domain located 
next to the C terminal known as Nogo 66. The second inhibitory domain on Nogo-A is a 
region located in its N terminus - known as amino Nogo. This latter domain is intracellular 
and has actions that are not cell type specific [16]. These two domains on the Nogo-A 
protein may act synergistically to inhibit neurite outgrowth in the injured CNS [16]. 
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1.4. Nogo Receptor (NgR) 
Although two inhibitory domains have been described for Nogo-A, only one receptor has 
been identified so far [17], binding the Nogo-66 domain of Nogo-A with high affinity and 
is therefore known as the Nogo-66 receptor, NgR. This receptor mediates the inhibition of 
axonal regeneration caused by Nogo-66 and it has been shown that expression of the 
receptor is sufficient to convert axonal growth cones from Nogo-66 insensitive to Nogo-66 
responsive [16]. The NgR is part of a family of three glycosylphosphatidylinositol (GPI) 
anchored proteins, called NgR-1,-2 and -3. NgR1 is known to interact not only with Nogo-
66 but also MAG and OMgp [18] which also act to suppress neurite outgrowth. Cleavage 
of NgR from the cell surface also renders axons insensitive to these ligands  [3]. This 
observation is very remarkable as there is no sequence similarity between these NgR 
ligands [19].  
 
The NgR is predicted to contain 473 amino acids [14] and is detectable as a ~85kDa band 
following denaturing SDS-PAGE [20]. In addition to a GPI anchor, it contains eight 
leucine rich repeats (LRRs), flanked by a cysteine-rich C terminal subdomain (LRRCT) 
and by a smaller leucine-rich N terminal domain (LRRNT) [19].  
 
NgR mRNA is expressed selectively in adult neurons [21], and the corresponding NgR 
proteins are found throughout axons in the adult and maturing CNS in a distribution in 
which they may receive signals from Nogo proteins. This matched distribution contrasts 
with MAG and OMgp which are expressed in many tissues where there is little or no NgR 
expression [21]. This suggests that, along with interacting with NgR to inhibit axonal 
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growth, MAG and OMgp, may have other roles and act on other receptors. Supporting 
this, it has been found that genetic deletion of NgR has only shown moderate disinhibitory 
effects suggesting that other receptors for Nogo, MAG and OMgp exist. Atwal et al. [22] 
found that paired immunoglobulin like receptor B (PIR-B), a type1 transmembrane 
glycoprotein, binds these ligands with high affinity, they also found that blocking this 
receptor partially rescues the neurite inhibition from Nogo, MAG, OMgp and that blocking 
both the PIR-B and the NgR receptors enables almost complete release from myelin 
inhibition. This group suggest that PIR-B may even be a more important factor in axonal 
growth inhibition than NgR as deletion of PIR-B resulted in greater neurite outgrowth than 
that achieved by deletion of NgR.  The fact that these structurally unrelated receptors can 
both bind three structurally unrelated ligands with high affinity highlights key complexities 
in the regulation of CNS tissue regeneration. 
 
1.5. p75
NTR
 
Since NgR is GPI anchored and lacks a cytoplasmic domain, the entire protein mass is 
located on the extracellular side of the membrane and therefore requires a transmembrane 
co-receptor to direct signal transduction into the cell. Wang et al [23] demonstrated that the 
molecule responsible for the transduction of inhibitory signals is a member of the TNF 
receptor family- the p75 neurotrophin receptor (p7
5NTR
) [23], it was found that the p75
NTR
 
specifically binds to NgR and is necessary for NgR mediated signalling. Furthermore, 
blocking experiments between NgR and p75
NTR
 caused a reduction in the inhibitory 
activities of Nogo, MAG and OMgp.  
 
737539 
 
14 
 
The p75
NTR
 - receptor is a 399 amino acid type 1 transmembrane protein, expressed in a 
wide variety of cells in the CNS during development. p75
NTR
 was originally identified as a 
neurotrophin binding receptor, with dynamic expression levels, declining to background 
levels in the adult CNS, but upregulated following CNS injury.  Neurotrophins are growth 
factors and include nerve growth factor (NGF), brain derived growth factor (BDGF) and 
neurotrophins 3, 4 and 5 secreted by sympathetic and sensory target organs as well as 
neurons and provide support to neurons as they reach their final target [24].  In a similar 
manner to p75
NTR
, neurotrophin production increases after injury to the nervous system 
[25] . When acting as an inhibitory mediator, the NgR/p75
NTR
 complex is activated by 
Nogo, MAG or OMgp, and p75
NTR
 acts as to release the small GTP binding protein RhoA, 
resulting in actin depolymerisation and growth cone collapse [26].  
 
The importance of p75
NTR
 in the formation of an active inhibitory receptor complex has 
been shown in many studies. Studies have shown that the extracellular domain of p75
NTR
 is 
necessary for its binding to NgR, whereas its intracellular and transmembrane regions are 
not necessary [23]. This study also demonstrated that blocking association of the 
extracellular region of p75
NTR
 with NgR inhibited the effects of the myelin breakdown 
products MAG, OMgp and Nogo-66. The intracellular domain was found to be necessary 
for transduction of the inhibitory signal across the membrane, as a truncated form of the 
receptor allowed robust neurite outgrowth [23]. Although p75
NTR
 has been shown to be an 
important factor in the inhibition of neurite outgrowth in vitro, its exact role is not fully 
established in vivo, not least because the tissue distribution of NgR does not correspond 
well to the distribution of p75
NTR
, and p75
NTR
 is not ubiquitously expressed in the adult 
brain where all the neurons are responsive to myelin inhibition [27]. Also, whilst p75
NTR
 
negative mice do not show RhoA activation or neurite outgrowth inhibition, when p75
NTR
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is co-expressed with NgR in non neuronal cells there was no activation of RhoA [28] in 
response to myelin breakdown products suggesting that although p75
NTR
 is necessary for 
the negative regulation of neurite outgrowth, other components must be involved too.   
 
1.6. TROY 
As p75
NTR 
is not widely expressed in the adult CNS, and CNS neurons are still inhibited by 
myelin breakdown products, it was postulated that there might be a functional homologue 
of p75
NTR
 that is more widely expressed in the adult CNS that would substitute p75
NTR
 in 
the NgR complex. These considerations led to the discovery of TROY, a member of the 
TNF receptor family, could bind to NgR with high affinity [29], and activates RhoA in 
response to myelin breakdown products. Unlike p75
NTR
, TROY is broadly expressed in the 
CNS, leading the authors to conclude that TROY can substitute for p75
NTR
 in the 
inhibitory receptor complex in the adult CNS.  
 
1.7. Lingo 1 
Lingo (LRR and Ig domain –containing, Nogo receptor-interacting protein) 1 was 
identified as a member of the inhibitory receptor complex, transducing signals across the 
membrane and is an important negative regulator of oligodendrocyte differentiation [30]. 
Lingo1 is a 614 amino acid protein [31] containing 12 leucine rich repeats which are 
flanked by a C- and N- terminal (LRRCT and LRRNT). The C-terminal region is 
composed of an immunoglobulin (Ig) domain, a transmembrane domain and a short 
cytoplasmic tail. Lingo-1 is a member of the LRRIg family of proteins which all contain 
leucine rich repeats (LRR) and immunoglobulin (Ig) domains, with several members 
involved in central nervous system development. Lingo1 has been shown to be present on 
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neural but not in non neural tissues, with highest expression levels found in the cortex [28]. 
Like p75
NTR
, Lingo1 expression is highest during embryogenesis and decreases thereafter 
to very low levels in adulthood.  
 
Lingo1 acts as an accessory molecule which acts to structurally and functionally stabilise 
the NgR/p75
NTR
 inhibitory complex, The in vitro actions of Lingo-1 have been examined  
in detail by Ji, B et al [32] who blocked Lingo-1 binding to NgR with a Lingo-1-Fc 
antagonist. The outcome was a significantly improved functional recovery, axonal 
sprouting and a decrease in RhoA activation, with similar in vitro results obtained by Mi, S 
et al 2004 [28]. However the functional significance of Lingo1 has not been demonstrated 
in vivo, with Lingo 1 antagonism resulting in only a very small difference in axonal 
sprouting, leading to the idea that more molecules may substitute for Lingo 1 in the 
inhibitory process.  
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Figure 1.1. Diagram showing the relationship between the various components 
involved in inhibition of axonal regeneration. 
The Nogo-66 protein acts on the NgR which forms a complex with p75
NTR
 or Troy and 
Lingo1 which act together to activate RhoA which results in an inhibition of growth. 
[3].   
 
1.8. An array based approach to identification of key components of the NgR 
complex. 
In a series of unpublished experiments (M Douglas, personal communication), researchers 
in the Molecular Neuroscience Group (University of Birmingham) performed a series of 
microarray experiments detailing gene expression profiles in a series of rat CNS injury 
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models. Amongst numerous differentially modulated genes, the gene for LRRIg receptor 
AMIGO3 was observed to be upregulated following traumatic injury. Of particular 
interest, the gene was additionally found to be downregulated in a modified CNS injury 
paradigm associated with axon regeneration. Subsequent results found that the addition of 
siRNA to AMIGO3 to in vitro cultures of dissociated dorsal root ganglia permitted neurite 
growth under otherwise growth inhibitory conditions. Collectively these data suggest a 
potential function for Amigo3 in the transmission of neuronal inhibitory signals after 
injury, but did not establish a molecular mechanism and suggesting further research was 
needed looking into the role of Amigo3 and the Amigo family of proteins in the formation 
and function of the NgR complex.  
 
1.9. Amigo  
The Amigo family of proteins, a subset of closely related LRRIg receptors, were first 
identified in experiments investigating the transcriptional effects of a protein called 
amphoterin, known to promote cell motility and neurite outgrowth. Expression of the 
amigo gene was induced by amphoterin giving it its name -Amphoterin induced gene and 
ORF (Amigo). Amphoterin, also known as HMGB1, is a heparin binding protein acting as 
a ligand for the receptor for advanced glycation end products (RAGE), initially discovered 
in rat brain but also subsequently identified in many cell types including fibroblasts [33].  
 
The Amigos are members of the LRRIg family of proteins of which Lingo1 is a member, 
and therefore contain both leucine rich repeats (LRR) and immunoglobulin (Ig) domains. 
Their LRRs are normally 20-29 amino acids long and consist of a beta sheet and  a helix 
connected by loops, forming a curved horseshoe shaped structure [34]. Leucine rich 
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repeats are found in a large number of proteins and act as interaction motifs. The domain 
arrangement consists of a type 1 transmembrane protein which containing six LRRs 
flanked by cysteine rich LRR -C and -N (LRRCT and LRRNT) terminals and an Ig 
domain close to the transmembrane region [35]. Further experiments functionally 
characterised the Amigo proteins, suggesting that the Amigo family manifest both 
homophillic and heterophilic binding properties. 
 
Individual amigo proteins are differentially expressed in tissues, with Amigo 1 mostly 
restricted to central nervous system tissues (cerebrum, cerebellum and the retina), whilst 
Amigo 2 and Amigo 3 expression was much more widespread (Fig.1.2). Amigo 2 was 
found to be expressed mostly in the cerebellum, retina, liver and lung with lower amounts 
found in other tissues and Amigo3 was shown to be expressed in all tissues tested in the 
study [35].  
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Figure 1.2. Location and structure of the Amigo proteins. 
 
a) The Amigo proteins have differing distributions with the body, whilst Amigo1 is 
almost exclusively expressed in the central nervous system, Amigo2 and 
Amigo3 are more widespread [35]. 
b) The Amigo proteins are made up of 6 leucine rich repeats (LRR) flanked by 
leucine rich N and C terminal domains, with an Ig domain close to the cell 
membrane followed by the transmembrane region and a short cytoplasmic tail 
[35].  
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1.10. Hypothesis 
Research to date suggests that axon inhibitory signaling pathways are dependent on the 
formation of a trimeric complex, consisting principally of NgR, p75
NTR
 and Lingo-1. The 
functional significance of this specific protein arrangement in vivo is unclear, however, a 
range of potential binding partners from the LRRIg family of proteins may substitute for 
components of this complex. This leads us to propose the hypothesis that members of the 
Amigo family of proteins may act as binding partners for NgR and/or p75
NTR
, substituting 
for Lingo-1 in the formation of an inhibitory signaling complex. 
 
1.11. Aims 
The project aims firstly, to clone human full length versions of NgR, p75
NTR
, Lingo1 and 
Amigo 1 to 3. Following this, these constructs will then be transiently expressed in 
mammalian cells, with the resulting proteins used in co- immunoprecipitation experiments 
to determine their relative binding specificities. 
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Figure 2.1. Plasmid map and multiple cloning site of pAAV-IRES-hrGFP.  
The vector map shows the position of the 3x FLAG tag after the multiple cloning site.  
2. Materials and Methods 
2.1. Materials 
 
Plasmids 
cDNA constructs were cloned into the expression vector pAAV-IRES-hrGFP (Stratagene). 
The vector contains an ampicillin resistance gene to allow antibiotic selection in bacteria, a 
CMV promoter for gene expression in mammalian cells and a multiple cloning site (MCS) 
followed by three tandem 3’ FLAG tag sequences. In addition, a hrGFP gene allows 
visualisation of transfected cells.  
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2.2. Methods 
 
PCR 
Polymerase chain reaction (PCR) was used to amplify Amigo1, Amigo2, Amigo3, and p75 
cDNA which had been obtained from GeneService and Lingo 1 and NgR cDNA which 
had been obtained from Thermo Scientific. The designed primers (detailed in the 
appendix) incorporated either 5’ EcoRI or BamHI sites and a 3’ XhoI restriction site to 
allow incorporation into pAAV-IRES-hrGFP cut with the corresponding enzymes. Stop 
signal codons were removed where desired, to produce a 3’ fusion with the tandem FLAG 
sequences from the plasmid vector. PCR reactions were performed using an ABI 9600 
thermal cycler with the following cycling conditions: an initial denaturation step of 96
o
C, 
followed by 18 cycles of 96
o
C for 30 seconds/55
o
C for 30 seconds/72
o
C for 90 seconds. A 
final 5 minute 72
o
C extension was used to complete the reactions. Amplification was 
carried out using either the Expand High Fidelity enzyme (Roche) or Pfu Turbo enzyme 
(Agilent).  
Typically, PCR reactions were prepared as follows: 
0.5-1µl Template DNA 
2µl forward and reverse primers at a concentration of 20pm/µl each 
1µl deoxynucleotide triphosphates (dNTPs) at a concentration of 10mM 
5µl of PCR buffer (10x) 
38-38.5µl H20 (up to 50µl) 
1µl PCR Enzyme 
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Overlap extension PCR 
Overlap extension reaction PCR was performed to perform either site directed mutagenesis 
or fuse cDNA sequences to create chimeric gene sequences. The approach uses a two step 
PCR reaction – in the first set of reactions, two PCR products are created – the 5’ product 
(A), using an external forward primer and an internal reverse primer, and 3’ product (B), 
using an internal forward primer and an external reverse primer. Each internal primer is 
designed to produce a mutually complimentary overlapping region of 36 base pairs. In the 
second reaction, the two PCR products are fused by using a mixture of (A) and (B) as 
templates, using the external primers only to create a single product (A+B). The mutated 
or chimeric product (A+B) is then cloned using standard techniques. 
 
Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments according to their length, 
with electrophoresis in 1% agarose gels in TAE, with 0.5µg/ml ethidium bromide added to 
allow visualisation of the DNA bands. Electrophoresis was performed using a current of 
80mA until clear separation of PCR products was observed. Sizing of PCR products was 
demonstrated using DNA ladders appropriate to their size, including the 100bp (Roche) 
and 1Kb DNA ladders (Fermentas/ Invitrogen).  PCR products were visualised under a low 
level UV light source and appropriate bands excised.  
 
Gel Purification 
Excised DNA bands were purified using Qiaquick spin columns (Qiagen) based on the 
standard spin protocol. The purified DNA was eluted into 30µl of elution buffer and stored 
at -20
o
C until required.  
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Restriction Digests  
Purified DNA was digested with relevant restriction enzymes (NEB), with restriction 
digests typically set up using 30µl of purified DNA, 4µl of appropriate NEB digestion 
buffer, 2µl of enzyme 1 (EcoRI or BamHI) and 2µl of enzyme 2 (XhoI) and 2µl of H20 for 
a total reaction volume of 40µl. Digests were performed at 37
o
C and incubated for 2 hrs. 
pAAV-IRES-hrGFP plasmid was similarly digested with appropriate enzymes, purified 
and stored at -20
o
C.  
 
Ligation 
DNA inserts were ligated into cut pAAV-IRES-hrGFP vectors under varying conditions 
ranging from room temperature for 1hr to 20°C overnight. The quantity of insert DNA 
required for the ligation reactions was determined by visualising levels of DNA and 
comparing against a known standard using agarose gel electrophoresis. The ligation 
reaction typically consisted of 2-5 µl insert DNA, 0.5-1µl of vector, 1µl of T4 DNA ligase 
enzyme, 1µl (10x) ligase buffer and H20 to a final volume of 10µl.  
 
Transformation  
Ligation mixes were transformed into chemically competent Top10 E.coli (Invitrogen) via 
heat shock treatment. Cells were thawed on ice, following which 4µl of the ligated vector 
mix was added.  After 30 minutes on ice the cells were heat shocked at 42
o
C for 30 
seconds before being placed back on ice for 2 minutes, following which 250µl of rich 
growth media SOC was added. The cells were incubated in an orbital shaker at 37
o
C for 
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1hr at 220 rpm before being plated onto LB/agar plates containing 100ug/ml ampicillin 
and incubated overnight at 37
o
C. 
 
Plasmid Mini Prep 
Single bacterial colonies were inoculated into 5mls of LB containing 100ug/ml ampicillin 
and incubated overnight at 37
o
C in an orbital shaker at 220 rpm. 3ml of the 5ml culture 
was centrifuged and from the resulting pellet, plasmid DNA was extracted using a Qiagen 
Mini Prep kit, following the mini spin protocol. DNA was eluted into 50µl of elution 
buffer (50 mM Tris pH 7.5) and stored at -20
o
C.  
 
PCR Screening 
Mini prep DNA was analysed by PCR to verify whether the gene of interest had been 
transformed successfully. For the PCR screening process, 2xBioMix (Bioline) was used 
which contains a 2x mix of Taq DNA polymerase enzyme, enzyme buffer and dNTPs. 
PCR reactions were set up as follows: 
1µl plasmid DNA 
2µl forward and reverse primers 
20µl BioMix (2x) 
15µl H2O 
An initial denaturation step of 96
o
C was used, followed by 18 cycles of 96
o
C for 30 
seconds/55
o
C for 30 seconds/72
o
C for 90 seconds. After the reaction had finished 10µl of 
the PCR mix were run on a 1% agarose gel. The gel was viewed under UV light to 
determine which clones contained the insert. 
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DNA Sequencing 
DNA sequencing was used to ascertain if any mutations were introduced into the DNA 
during the PCR and cloning process. Sequencing reactions were set up by adding 7µl of 
the mini prep DNA to 7µl of H2O and adding 1µl of the appropriate sequencing primer 
(final primer concentration 3.5 pmol). To ensure full coverage of cloned inserts, three 
primers were used,  the first being a Beta globulin primer, priming for the 5’ region of the 
insert, followed by two internal primers at appropriate intervals (designed internal primer 
sequences in the appendix). Sequences were analysed using Sequencher software.  
 
DNA Midi Prep 
Midi scale DNA preparations were performed to produce sufficient quantities for 
eukaryotic cell transfection. A single colony was picked from a cloning plate, and grown 
in 100ml of LB/ampicillin (100ug/ml) overnight at 37
o
C. DNA was purified using 
NucleoBond Xtra Midi columns (Clontech) according to standard protocols. Following the 
purification steps the DNA was eluted into 5ml of elution buffer then precipitated with 
isopropanol, 70% ethanol and finally resuspended into 100µl of 50 mM Tris pH 7.5.  
 
DNA quantification 
DNA obtained from the midi preparations was quantified using nanodrop apparatus 
(Thermo scientific) using absorbance readings at 260 nm. 1.5µl samples were analysed, 
using H20 as a blank. Resulting DNA concentrations were calculated in ng/µl and samples 
were normalised to a final concentration of 1000 ng/µl (1µg/µl) using 50 mM Tris pH 7.5.  
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Transfection 
Eukaryotic cell transfection was carried out using COS cells using Lipofectamine 2000 
(Invitrogen) reagent in six well plates. Cells were plated 48h before transfection at cell 
densities of 1-2x10
5
 cells/well in Dulbecos modification of Eagles medium (DMEM), 10% 
foetal calf serum without antibiotics,. Cells were viewed under a light microscope before 
transfection to verify that they were 90-95% confluent. For transfection, per well, 4µg of 
DNA was diluted in 50µl of Opti-MEM I medium (Invitrogen). In a separate tube, 
Lipofectamine 2000 was also diluted in Opti-MEM I reduced serum medium (10µl in 
50µl). These dilution products were combined, incubated for 20 minutes and the 100ul 
resultant mix added drop wise to the COS cells. Cells were returned to the 37
o
C incubator 
for a further 48-72 hrs. Following this, cells were harvested into 1ml of sterile PBS, 
centrifuged and the cell pellets were stored at -20
o
C. Cell pellets were lysed using lysis 
buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1mM EGTA, 1% Triton X) 
and the cellular extracts were stored at -80
o
C.  
 
Quantifying the protein 
The protein concentration in produced from COS cell lysates were quantified using a 
BioRad Dc protein assay kit, using a 96- well flat bottom plate and bovine serum albumin 
as a standard control. Samples were added neat and 1:5 diluted in PBS or lysis buffer, a 
standard curve was produced using serial dilutions of BSA, at 2, 1, 0.5, 0.25, 0.125, 0.063 
and 0.031 mg/ml respectively. Readings were measured using a wavelength of 750 nm.  
 
 SDS-PAGE and Western Blots 
SDS-PAGE and Western Blots were used to visualise proteins that were present in the 
transfected cell lysates. 12.5% polyacrylamide gels were made for the separation of the 
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proteins, samples were prepared using 5x SDS+DTT buffer, various volumes were loaded 
onto the gels and transferred onto a polyvinylidene fluoride (PVDF) membrane allowing 
for visualisation of the proteins. Blots were blocked with 5% milk powder in TBS-Tween 
(1%) for 1hr at room temperature or overnight at 4°C. After blocking the blots were 
probed with primary antibodies (see table). The secondary antibodies used were goat anti 
mouse and goat anti rabbit antibodies conjugated to horse radish peroxidise (1:20000) 
(Sigma) and proteins were visualised by enhanced chemiluminescence (ECL) substrate 
and autoradiography.  
 Antibody Dilution Source 
Amigo1-Flag Mouse anti-Flag 1:1000 Sigma F3165 1MG 
Amigo2-Flag Mouse anti-Flag 1:1000 Sigma F3165 1MG 
Amigo3-Flag Mouse anti-Flag 1:1000 Sigma F3165 1MG 
NgR Mouse anti-NgR 1:500 R& D Systems MAB1208 
500ug 
p75
NTR
 Rabbit anti-NGFR 
Mouse anti-NGFR 
1:1000 
1:1000 
Promega G323A 
Millipore MAB5264 
β actin Mouse anti- actin 1:10000 Sigma A5441 
Table 2.1. Antibodies used in western blots. 
Stripping and re-probing the membrane 
After the protein of choice had been detected on the membrane, the membrane was treated 
with mild stripping buffer (1.5% glycine, 0.1% SDS, 1% Tween-20 pH 2.2) then re-probed 
for actin to quantify protein loading. The buffer was added to the membrane for 3hrs after 
then washed twice in PBS, for 5mins each and twice in TBS-Tween, for 5mins each. 
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Deglycosylation 
Deglycosylation was performed by adding 4µl of Glycoprotein denaturing buffer (NEB) to 
20µl of cell lysates and 16µl of H2O and boiling for 10 minutes. This was followed by 
taking 10µl of this reaction and adding 2µl of G7 reaction buffer, 2µl of NP40 and 1µl 
PNGase F followed by a 1hr incubation at 37
o
C. These samples were treated in a similar 
manner to that of the glycosylated ones by adding the appropriate volume of 5x sample 
buffer +DTT and boiling for 5 minutes.  
 
Co-Immunoprecipitation 
Co-IPs were performed to determine the binding properties of the proteins of interest. 
DNA in various combinations was transfected into COS cells, 4µg of each construct were 
added to the cells which were left to grow for 48hours before being harvested and lysed. 
The cell lysates were then mixed with either anti-FLAG (M2 affinity beads, Sigma) or 
anti-HA (anti-HA affinity matrix, Roche) beads for 2hours, the beads were then washed 
with lysis buffer twice and finally sample buffer +DTT was added and the beads were 
boiled for 2minutes. Samples were stored at -80
o
C and analysed by western blot. 
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3. Results 
3.1 Cloning of NgR, p75 and Amigo 1-3. 
 
NgR, p75
NTR
 and Amigo 1, 2 and 3 products were produced by PCR. FLAG tags were 
incorporated into the Amigo 1, 2 and 3 constructs by removing the native 3’ stop codons 
leading to fusion with the recipient plasmid (pAAV-IRES-hrGFP) 3x FLAG sequences, 
whilst NgR and p75 were left in their native forms. Primers incorporating EcoRI, BamHI 
or XhoI restriction sites were used for cloning and the products of PCR amplification were 
run on agarose gel electrophoresis for analysis and purification. Amigo1 contains EcoRI 
and XhoI restriction sites and the PCR product is 1476bp in size, Amigo 2 contains BamHI 
and XhoI restriction sites and the products are 1569bp in size (Figure 3.1). The native 
Amigo 3 cDNA sequence contains internal BamHI and EcoRI sites, precluding 
straightforward cloning. The internal BamHI site was therefore mutated by overlap 
extension PCR, a two step PCR process in which, in combination with external primers, 
overlapping internal mutagenic PCR primers are used to create two intermediate 
complimentary products. The two products are then fused using a subsequent PCR step to 
create a full length PCR product containing the desired mutant (in this case removing an 
internal BamHI site) (Fig 3.2.). NgR and p75
NTR
 cDNA did not contain any internal 
restriction sites so straightforward PCR reactions were carried out as for Amigo 1 and 
Amigo 2. 
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Figure 3.1. Gel electrophoresis of digested Amigo1 and Amigo2 inserts. 
Lane 1 shows the 100bp DNA ladder (Roche), lane 2 contains digested Amigo1 at 
1476bp and lane 3 contains digested Amigo2 at 1569bp.  
1       2             3
 3  
PCR products were analysed by agarose gel electrophoresis along side a DNA ladder to 
determine if the reaction had worked and produced a product and that the product was of 
the correct size. Next, bands containing DNA of the correct sizes were excised from the 
agarose and the DNA was purified and digested for 2hours with either EcoRI and XhoI or 
BamHI and XhoI to produce sticky ends on the DNA insert. The digested products were 
analysed by agarose gel electrophoresis (Figures 3.1 and 3.3) followed by excision of the 
DNA bands and purification of the DNA ready for ligation.  
 
2500 
1000 
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500 
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Figure 3.2. Products of overlap extension PCR. 
Lane 1 shows the 1Kb DNA ladder (Fermentas). Lanes 2 and 3 and 4 and 5 show the 
products of the first step of the mutagenesis of Amigo 3, with the 5’ product in lanes 
(2+3) and 3’ product in lanes (4+5), with an overlapping region including the 
mutagenised BamHI site. The products were fused together via a subsequent PCR step 
to form a single full length Amigo 3 without the internal BamHI restriction site.  
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Figure 3.3. PCR amplification and digestion of NgR and p75
NTR
. 
Lane 1 shows the 1Kb DNA ladder (Fermentas) NgR and p75
NTR
 digestion products are 
shown in lanes 2 and 3 respectively. 
 
 
 
   1           2              3 
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2000bp 
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The pAAV-IRES-hrGFP vectors were digested with the same combination of enzymes 
(BamHI/XhoI or EcoRI/XhoI), dephosphorylated for 30 minutes (Antarctic phosphatase, 
NEB) and gel purified. Cut plasmid and digested PCR products were ligated using T4 
DNA ligase for between 1 hour and overnight. The ligation mixes were transformed into 
chemically competent E.coli cells (Top10 cells) by heat shock which were then plated onto 
LB/agar/ampicillin plates overnight. Typically, six single colonies were picked off each 
plate and grown overnight in 5ml LB media.  Bacterial cultures were then mini prepped to 
extract the DNA from each. The mini prepped DNA was PCR screened, using the primers 
that were used to originally amplify the DNA, to see which of the clones contained the 
insert (Figure 3.4). 
 
737539 
 
35 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Analysis of clones containing DNA inserts.  
Lanes 1-6 show Amigo 1 clones after PCR screening, clones 1 and 6 contain the DNA 
insert. 
Lanes 7-12 show Amigo 2 clones after PCR screening, clones 7, 8, 10, 11, and 12 all 
contain the DNA insert.  
 
           1      2    3     4     5     6            7     8     9    10   11   12 
The presence of an insert was confirmed by DNA sequencing, initially using a β-globin 
primer which binds 5’of the DNA insertion site, enabling determination of the DNA 
sequence before the insert and then typically 800 bases of the insert itself. Positive clones 
were then sequenced using appropriate internal primers (Table 2. Appendix) and analysed 
using Sequencher software (figures 3.5 and 3.6), comparing the DNA sequence results to 
the known nucleotide sequences for that protein acquired from the NCBI nucleotide 
database. All constructs were sequenced along their full length to confirm they 
corresponded to the designed sequence and were free of mutations. 
 
 
 
500bp 
1500bp 
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1000b
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Figure 3.5. DNA sequencing results of 5’ end of representative clone containing 
Amigo1. 
DNA sequence results of an Amigo 1 clone using the β- globin primer (red arrow) 
compared to the known sequence for Amigo 1 (green arrow) as shown in Sequencher 
software. The EcoRI restriction site is boxed in red; this is followed by the Amigo 1 
DNA insert. The chromatogram is shown below; each peak represents a different 
nucleotide with red being thymine (T), green representing adenine (A), black 
representing guanine (G) and blue representing cytosine (C).   
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Figure 3.6. DNA sequencing results of 3’ end of clone containing Amigo 1. 
DNA sequence results of Amigo1 followed by 3 FLAG tags analysed in Sequencher 
software. The Amigo 1 clone DNA sequence (red arrow) is compared to the known 
Amigo1 sequence (green arrow). The XhoI restriction site is boxed in red on both the 
base sequence and the chromatogram, the FLAG tag sequence is shown by the white 
letters on a black background. The Chromatogram is shown for the Amigo1 clone; each 
peak represents a different nucleotide with red being thymine (T), green representing 
adenine (A), black representing guanine (G) and blue representing cytosine (C).   
 
 
 
Colonies corresponding to analysed NgR, p75, Amigo1, Amigo2 and Amigo3 clones were 
expanded in 100ml cultures to allow larger scale preparation of the DNA using a midi prep 
kit. The concentration of DNA extracted was measured by nanodrop and then all DNA was 
diluted to a concentration of 1000ng/ul (1ug/ul) with elution buffer for further use.  
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a)          b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Results from BioRad Dc Protein Assay.  
a) Layout of plate; BSA was added in duplicate to the dark blue columns in the 
concentrations (mg/ml) indicated, samples were added in duplicate to the pale 
blue wells neat and diluted 1:5. 
b) OD readings from plate reader; the readings for the proteins were compared to 
the readings for the BSA control. 
 
 
3.2. Analysis of Amigo, NgR and p75
NTR
 expression/ Expression of Amigo, NgR and 
p75
NTR
 constructs in mammalian cells.  
Amigo 1, 2 and 3 (-FLAG) were transfected into COS cells, using the Lipofectamine 2000 
(Invitrogen) method. Following transfection, COS cells were grown for between 48 and 72 
hours at 37
o
C, following which they were harvested and lysed with lysis buffer. To 
determine the concentration of protein in the cellular lysates a protein assay was 
performed, where the cell lysates were compared to a BSA at known concentrations, 
starting at 2mg/ml, followed by seven doubling dilutions. Cell lysates were added neat and 
diluted 1:5 to ensure OD readings over a linear range of concentrations, with all samples 
run in duplicate. The plate was read in an ELISA plate reader and the average OD reading 
of the duplicates was used to determine protein concentrations. 
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Figure 3.8. Western Blot analysis of the Amigo 1, 2 and 3 proteins. 
Lanes 1 and 5 show COS cell lysates, 2 and 6 show Amigo1 cell lysates, 3 and 7 show 
Amigo2 cell lysates and lanes 4 and 8 show Amigo3 cell lysates. Lanes 1-4 were loaded 
with 10µl of cellular lysates and lanes 5-8 were loaded with 2µl of cellular lysates. 
Lanes 3 and 7 contain a small molecular weight species at around 20 kDa, these are 
indicated by the arrow heads. 
 
75kDa 
The protein assay indicated that, broadly speaking, the lysate concentrations were roughly 
equivalent. As the subsequent analyses were semiquantitative only and would use western 
blotting for actin as a loading control, no dilutions were made for the protein lysates 
. 
Following the protein assay, proteins were analysed by Western Blot to determine their 
relative sizes. Amigo 1,2 and 3 cell lysates were prepared using Sample buffer + DTT and 
run on 12.5% SDS gels, with 10 µl and 2 µl samples of each run in parallel. Proteins were 
then transferred onto nitrocellulose membrane, the membrane was then blocked in 5% 
milk, washed, and probed with a mouse anti-FLAG antibody then with a goat anti mouse 
2
o
 antibody conjugated to HRP before being developed by ECL (Figure 3.8). 
 
   1            2            3            4          5          6            7         8 
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Figure 3.9. Deglycosylation of Amigo proteins.  
Lanes 1, 3 and 5 contain Amigo 1, Amigo 2 and Amigo 3 cell lysates respectively. 
Lanes 2, 4 and 6 contain the Amigo 1, Amigo 2 and Amigo 3 cell lysates after 
deglycosylation respectively. Lane 7 contains the COS cell lysate. 10µl of sample was 
added to each lane.  
 
 
 
The Western Blot showed us that the Amigo proteins were successfully expressed in COS 
cells, the Amigo proteins are shown to be roughly 75kDa in size, with Amigo 1 and Amigo 
2 running as doublets. In addition, the lanes corresponding to the Amigo 2 protein lysate 
consistently displayed a small band at 20 kDa, potentially indicating cleavage of full 
length Amigo 2 to produce a free or membrane bound intracellular domain. The observed 
protein doublets could result from differential gylcosylation, so the protein lysates were 
treated with PNGase (also known as N-Glycosidase F) to hydrolyse and remove N-glycan 
chains. The enzyme cleaves between the innermost GlcNAc and asparagine residues of 
high mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins to 
reveal monomeric forms of proteins. After deglycosylation the Amigo proteins were 
analysed as before by Western Blot alongside the original glycosylated proteins (Figure 
3.8), this showed that the double bands were due to differential glycosylation as they 
became singular after enzyme treatment. The size of the proteins changed due to this and 
the more realistic estimate of the size of the products now approximates to 55 kDa.  
 
75kDa 
50kDa 
       1              2              3              4               5             6             7 
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a)                                                                              b) 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. NgR and p75
NTR
 cell lysates probed with anti-NgR or anti-p75
NTR
 
antibodies. 
a) Western blot using an antibody against NgR. Lane 1 contains COS cell lysates, 
lane 2 contains NgR cell lysates and lane 3 contains p75
NTR 
cell lysates.  
b) Western blot using an antibody against p75NTR. Lane 1 contains COS cell lysates, 
lane 2 contains NgR cell lysates and lane 3 contains p75
NTR
 cell lysates. 
2ul of each sample was added to the wells. 
 
COS cells were also transfected with NgR and p75
NTR 
constructs and again left to grow for 
48-72 hours. Lysates were analysed by western blots using anti- NgR and anti- p75
NTR
 
antibodies.  Membranes were stripped using stripping buffer and then re-blocked and re-
probed for actin. 
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These western blots showed that the transfections with NgR and p75
NTR
 were successful 
and the proteins were present in the cellular lysates, without cross-reactivity between NgR 
p75
NTR
 antibodies. 
 
Once individual protein expression was established next we wanted to investigate how the 
different molecules interact when expressed together. Co-IP experiments were performed 
to see if any of the Amigos would bind to NgR or p75
NTR
. Relevant combinations of 
plasmids were transfected into COS cells, which were grown for 48hrs then lysed as 
before. Anti FLAG beads were added to cellular lysates and mixed, washed and run by 
SDS-PAGE as before. The blots were then probed with anti-NgR or anti-p75
NTR
 
antibodies.  
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a)                                                                          
 
 
        
 
    IP anti-FLAG, WB anti NgR 
 
 
 
 
 
 
 
    IP anti-FLAG, WB anti                                    
 p75
NTR
 
 
 
 
Figure 3.11. Co-IP experiments of the Amigo proteins with NgR and p75
NTR
. 
a) Lane 1 contains COS cell lysate, lanes 2, 3, and 4 contain NgR + Amigo1, Amigo 
2 and Amigo 3 co-IPs respectively. Lanes 5, 6, and 7 contain NgR+ p75
NTR
 + 
Amigo1, Amigo2 and Amigo3 co-IPs respectively (as do lanes 13, 14 and 15). 
Lane 8 contains NgR cell lysate. 
b) Lane 9 contains COS cell lysate, lanes 10, 11 and 12 contain p75NTR + Amigo1, 
Amigo2 and Amigo3 co-IPs respectively lane 16 contains p75
NTR
 cell lysates. 
 
 
 
 
 
 
       b) 
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Immunoprecipitating with anti FLAG blotting with anti- p75
NTR
 produced bands 
corresponding to the size of p75NTR, suggesting co-immunoprecipitation of p75
NTR
 with 
Amigo 1, 2 and 3 (lanes 10, 11, 12). The band intensity was reduced significantly in 
lysates with Amigo 1-3 and both NgR and p75 lanes (13, 14, 15). These results could 
indicate differential binding of individual Amigo proteins to p75
NTR
, which could be 
further influenced by the presence of NgR. Alternatively, particularly as the method is only 
semiquantitative at best, the findings could be a consequence of interference of individual 
plasmid constructs with one another during the transfection process (for example, the 
addition of NgR plasmid to the transfection mix could reduce the efficiency of p75
NTR
 
plasmid transfection). 
 
Results from the anti NgR probing were more difficult to interpret, with numerous bands 
present in all wells (including non transfected COS lysates). The most prominent bands 
were 55kDa in size, suggesting that these bands were potentially contaminating 
immunoglobulin heavy chains from the beads – which would have been detected by the 
secondary antibody (goat anti mouse) in the western blot stage. 
 
The co-IP experiment had so far been looking at what binds to the Amigo proteins by 
using anti-FLAG beads, but the NgR and p75
NTR
 constructs made were not tagged so it 
was not possible to isolate these proteins and see what binds to them. It was decided to tag 
NgR and p75
NTR
 with a HA tag so that co-IP experiments could be performed using anti-
HA beads. Overlap extension PCR was performed on the NgR and p75
NTR
 DNA constructs 
to add the HA tag then the co-IP experiments were performed by transfecting the COS 
cells as before with different combinations of the DNA of interest. The beads were anti-
HA beads which were mixed with the cell lysates to bind to and isolate the proteins with 
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a)                                                             b)                                                      
  
 
 
 
 
 
 
      IP anti-HA, WB anti FLAG             IP anti-HA, WB anti FLAG 
 
c) 
 
 
 
 IP anti- HA, WB anti FLAG 
Figure 3.12. Co-IP experiments with HA tagged NgR and p75
NTR
 and the Amigo 
proteins.  
 a) Lane 1 contains the NgR cell lysate, lanes 2, 3 and 4 show NgR-HA 
immunoprecipitated with Amigos1, 2 and 3 respectively.  
 b) Lane 1 contains the p75NTR cell lysate, lanes 2, 3 and 4 show P75NTR-HA 
immunoprecipitated with Amigos1, 2 and 3 respectively. 
 c) Lanes 1, 2 and 3 show NgR+p75NTR and Amigos1, 2 and 3 respectively.  
HA tags on and consequently those proteins that were in turn bound to them. The beads 
and their bound proteins were boiled with Sample buffer +DTT and loaded into a 12.5% 
protein gel, the blots were then probed with anti-FLAG antibodies which would reveal of 
any of the Amigo proteins bound to the NgR or p75
NTR
 protein. 
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To make to most of the different ways in which a co-IP could be carried out we decided to 
clone various versions of the Amigo proteins, i.e. we made wild type versions, HA tagged 
versions and double tagged HA/FLAG versions to go along with the FLAG tagged Amigo 
proteins already made.  
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4. Discussion 
Human Amigo 1 and Amigo 2 were cloned successfully into mammalian expression 
vectors, as was human Amigo 3, which was cloned with its internal BamHI restriction site 
removed by mutagenesis. All three of the Amigo constructs had their stop codons 
removed, resulting in the incorporation of triple FLAG tag sequences to their 3’ ends (from 
the expression vector), to enable identification and isolation. DNA sequencing throughout 
the length of the respective genes revealed that no mutations had occurred during the 
cloning processes. Amigo 1, Amigo 2 and Amigo 3 plasmid DNA were subsequently 
transfected into COS cells. Human NgR and p75
NTR
 were also cloned successfully, using 
standard approaches, as no internal restriction sites had to be removed and no tags were 
added to the 3’ end of the DNA. Similarly, no mutations were found in the cloned DNA of 
NgR or p75
NTR
 after sequencing. DNA was transfected into COS cells and cellular lysates 
were analysed by western blot to determine the transfection efficiency and levels and 
patterns of protein expression. Western blots (figure 3.8) revealed high levels of 
expression for Amigo 1, Amigo 2 and Amigo 3 which are around 70 kDa in size. Of 
interest, a significant lower molecular band was consistently identified in the Amigo 2 cell 
lysate, at around 20 kDa, suggesting the protein is potentially cleaved. The specific 
cleavage site is the subject of speculation, but would be likely to be extracellular but 
membrane proximal, to incorporate the cytoplasmic domain which contains the FLAG 
sequences essential for detection. This assumption is based on the observation that the 
transmembrane region is 21 amino acids (residues 399-419) and intracellular domain 103 
amino acids long (amino acids 420-522) respectively. The calculated size for these two 
regions is 2257 and 10831 daltons, to which the FLAG tag region would be added. 
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In this western blot the Amigo protein bands were shown as doublets which made an 
accurate evaluation of molecular masses difficult. The pattern could be the result of 
impurities or breakdown products, but a more likely cause for the doublet appearance was 
of variable glycosylation. It is predicted that Amigo 1 has N-linked gylcosylation sites on 5 
amino acids (residues; 7, 264, 315, 349 and 360), Amigo 2 has N-linked gylcosylation 
sites on 8 amino acids (residues; 58, 104, 281, 288,345, 373, 381 and 384) and Amigo 3 
has N-linked gylcosylation sites on 5 amino acids (residues; 107, 272, 301, 362, 368) 
(UniProtKB protein database). This possibility was therefore analysed by deglycosylating 
the relevant cell lysates using PNGase, an enzyme which removes almost all N-linked 
oligosaccharides from glycoproteins. The deglycosylated protein lysates were analysed 
alongside their glycosylated counterparts (figure 3.9) by Western blot. Bands produced by 
the deglycosylated proteins now migrated as singlets, shifting their apparent molecular 
weight to 60 kDa. 
 
In contrast, Western blots performed on NgR and p75
NTR
 cell lysates (figure 3.10) revealed 
only single major bands at 120 kDa (NgR) and 75 kDa (p75
NTR
) showing no clear 
differential glycosylation. The blot did however show a number of potential breakdown 
products in the NgR lysate, although this suggestion will require further analysis. This 
phenomenon has been previously described [36], in which an NgR construct transfected 
into CHO cells produced NgR species migrating at 64 kDa and 48 kDa, speculated to be a 
C-terminally truncated NgR fragment. In addition, the blotting also suggested that there 
was no cross reactivity between the NgR and p75
NTR
 antibodies.  
 
Following preliminary experiments where expression of the proteins alone was analysed, 
co-immunoprecipitation experiments were performed to determine the binding properties 
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of those proteins to one another. COS cells were transfected with Amigo 1, 2 or 3 DNA 
plus NgR and/or p75
NTR
 DNA, allowed to grow for 48-72hrs and lysed. Initially anti-
FLAG beads were used and were added to the COS cell lysates allowing the Amigo 
proteins to bind via their FLAG tag regions. The beads were washed and analysed by 
western blot using antibodies directed to either NgR or p75
NTR
 to determine if either of 
these proteins had bound to the any of the Amigo proteins. The blots (Figure 3.11) showed 
that the anti NgR antibody was poor because the antibody bound in all cases even in the 
COS cell lysate (which contained neither Amigo nor NgR). Probing for p75
NTR
 gave more 
promising results, revealing that p75
NTR
 binds to Amigos 1 and 3 with and without NgR 
present and binds Amigo 2 in the absence of NgR.   
 
Because of the promising results obtained from the first set of co-IP experiments, NgR and 
p75
NTR
 were cloned with the addition of N-terminal HA tags. Co-IP experiments were then 
performed using anti-HA beads to bind to either NgR or p75
NTR 
in the COS cell lysate, the 
beads were analysed by western blot and probed using anti FLAG antibody to see if any of 
the Amigo proteins had bound. The western blot (figure 3.12) revealed a large amount of 
binding between NgR and Amigos 1 and 3 with and without p75
NTR
 present, and also 
showed that p75
NTR
 binds to Amigos 1 and 3 with and without NgR present. There is a 
small amount of binding between Amigo 2 and NgR and p75
NTR
 alone and when NgR and 
p75
NTR
 are expressed together which corresponds to the idea that Amigo2 binding is 
reduced due to the cleavage of an important region.  
 
 
Future work 
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The experiments presented above need further replication, with investigation of the 
binding properties using a range of alternative biochemical and biophysical approaches. 
Some of these require the use of detergent free soluble proteins (therefore lacking their 
transmembrane regions). The proteins will therefore need to be expressed as protein 
ectodomains (best achieved using our established S2 drosophila system), preferably with 
structural variants to include the LRR region of each of Amigo protein, as well as the LRR 
regions plus the Ig region of the protein. Following successful expression, these proteins 
would be attached to a BiaCore chip and recombinant NgR and p75
NTR
 proteins would be 
flowed over the chip to test for binding. As an alternative, the NgR and p75
NTR
 proteins 
could be bonded with the chip and the Amigo ectodomains can be flowed over. Also, it 
would be useful to determine the structure of the expressed ectodomains of the Amigo 
proteins and X ray crystallography would be a good method to use for this.  
 
It will be important to confirm that the proteins are expressed at the cell surface in native 
form. There are several experimental approaches that could be used, the most 
straightforward would consist of biotinylation of the cell surface of transfected cells (using 
a membrane impermeant form of biotin), followed by precipitation of biotinylated proteins 
with streptavadin-agarose and subsequent western blotting for proteins of interest. 
Alternatively, high resolution microscopy (confocal for example) could also be used to 
localise transfected proteins. 
 
Another area to continue with would be the cloning of the DNA for all the proteins of 
interest in their native forms as well as with different tags on, i.e. for each protein there 
would be: wild type (WT), (amino-terminal) HA tagged, (carboxy-terminal) FLAG tagged 
and HA+FLAG tagged combinations, this will enable us to fully characterise the 
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respective binding and potential cleavage properties of these proteins, as suggested by the 
Western blotting patterns of Amigo 2. 
 
Lingo is the best characterised component of the NgR/p75 complex and it would be 
desirable to repeat the co-immunoprecipitation experiments, using this protein as a positive 
control and potentially make semiquantitive assessments of comparative binding 
properties, including any heterophilic association with Amigo family members. Alongside 
this, similar experiments should be performed using TROY; as this protein is thought to 
substitute for p75
NTR
 and is more widely expressed in the CNS and may have a more 
important function. 
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Abstract 
Mesenchymal stem cells (MSCs) are non haematopoietic cells capable of differentiating 
into adipocytes, chondrocytes and osteoblasts they are positive for CD105, CD90 and 
CD73 and negative for CD34 and CD45 amongst others. MSCs are not immunogenic and 
do not stimulate alloreactivity and this characteristic along with their ability to differentiate 
into such a range of cell types make them attractive for use in regenerative therapies by 
systemic infusion of ex vivo expanded cells. It s not known how MSCs are recruited from 
the circulation, however they may employ mechanisms similar to those used by leukocytes 
and haematopoietic stem cells when they are transported from the circulation such as the 
employment of selectins and via the aid of platelets. We therefore wanted to determine if 
MSCs can bind to collagen or P selectin coated microslides under flow conditions and in 
parallel observe if platelets as a whole can bind to MSCs in a variety of conditions by 
staining MSC and blood samples with CD105 (MSC marker) and CD42b (platelet marker) 
and use flow cytometry to looking at the effects of anticoagulant, time and platelet 
activation. The results demonstrated that MSCs do not bind to collagen or P selectin under 
flow conditions and demonstrated that a small proportion of platelets can bind to MSCs 
under appropriate conditions. Further, the binding experiments revealed that platelet 
activation reduced the level of binding between MSCs and platelets.  
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5. Introduction 
Mesenchymal stem cells (MSCs) have potential to be used therapeutically due to their 
capability to differentiate and regenerate tissue and their immunomodulatory effects.  
However, little is known about the mechanisms by which they are recruited from the 
circulation to their target tissues if infused. In order to gain more insight into the mode of 
action of MSCs this report will look at the adhesive characteristics of MSCs that might aid 
in their recruitment, in comparison to the previously described methods employed by 
leukocytes and haematopoietic stem cells.  
 
5.1. Types of stem cell 
Stem cells are progenitor cells that have the ability for unlimited self renewal, maintaining, 
at the same time, the ability to differentiate into mature lineages  [37], with each daughter 
cell having a more restricted differentiation potential and more specific phenotypic 
characteristics [38] . The most naïve stem cells are totipotent stem cells which can 
differentiate into embryonic as well as extraembryonic cells.  Following these are 
pluripotent stem cells also known as embryonic stem cells (ESC) which are derived from 
the inner cell mass of the blastocyst.  These cells can differentiate into all the cells of the 
three germ cell layers: the ectoderm, endoderm and mesoderm. It is this pluripotency that 
differentiates embryonic stem cells from adult stem cells which are more restricted 
multipotent cells capable of differentiating into a limited number of cell types.  These adult 
stem cells, also known as somatic stem cells, are life long cells that exist to replenish cells 
as they die, either by normal wear and tear or by injury [39] and although they are classed 
as multipotent they retain some of the features of their pluripotent progenitors such as their 
ability to endlessly self renew. Haematopoietic, neural and mesenchymal are all types of 
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Figure 5.1. Diagrammatic representation of the differentiation of stem cells derived 
from bone marrow.  
HSCs derived from the bone marrow differentiate into cells of myeloid (e.g. monocytes 
and neutrophils) and lymphoid (e.g. T and b cells) lineage. MSCs derived from the bone 
marrow differentiate into a number of cell types including chondrocytes, adipocytes and 
osteoblasts. [40].  
multipotent adult stem cells. In some animals stem cells can sometimes be identified quite 
precisely by their morphology and location [40] but in humans, stem cells are defined by 
their function, i.e. what cells they become. Haematopoietic stem cells (HSCs) are easily 
identifiable as differentiating into cells of myeloid lineage such as eosinophils, 
macrophages and neutrophils, and cells of lymphoid lineage such as NK cells, T cells and 
B cells. HSCs are stored in the bone marrow at a frequency of 1: 10000 to 1:100000 total 
blood cells [41]. Neural stem cells differentiate into neurons and glia, and mesenchymal  
stem cells differentiate into a variety of cells including osteocytes, adipocytes and 
chondrocytes.       
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5.2. Mesenchymal Stem Cells 
Mesenchymal stem cells are non haematopoietic cells capable of differentiating into 
adipocytes, chondrocytes and osteoblasts and contribute to the renewal of adipose tissue, 
cartilage, bone, muscle, myocardium and marrow stroma [42], illustrating their diversity 
and meaning that MSCs are attractive for use in stem cell therapies. MSCs are so called 
because of their ability to differentiate into mesenchymal type cells, but it has been 
suggested many times that this may not be the most appropriate name to describe these 
cells as they differentiate into cells of both mesodermal and non mesodermal lineages i.e. 
ectodermal and endodermal lineages, and are therefore characterised as multipotent. 
Because of this, mesenchymal stem cells are often also referred to as; fibroblast colony 
forming units (CFU-Fs), bone marrow stromal cells [43], multipotent stromal cells or 
mesenchymal progenitor cells.   
 
Phenotypically, MSCs have been difficult to classify because they display a great 
heterogeneity and many of the characteristic markers used to identify these cells are also 
exhibited by other cells. But despite the fact that no unique markers for MSCs have been 
found yet, their cell surface antigen expression profile has been well characterised; it has 
been shown that MSCs, unlike HSCs, are CD34
-
 and CD45
-
. MSCs have however been 
shown to be positive for; CD10, CD13, CD90, CD105, CD109 and CD164 among others 
[44] and are also HLA class 1 positive [45]. With these findings in mind the Mesenchymal 
and Tissue Stem Cell Committee of the International Society for Cellular Therapy came up 
with a set of guidelines to define MSCs [46], these were: cells must first be positive for 
CD73, CD90 and CD105, second they must be negative for HSC marker CD34, and 
leukocyte marker CD45 as well as CD14 or CD11b, and CD79a or CD19, and HLA-DR 
[47]. To term a cell an MSC it must also be plastic adherent and must be able to 
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differentiate into adipocytes, osteoblasts and chondroblasts under specific in vitro 
differentiating conditions [48]. It is worth noting that the above definitions are based on 
cells cultured in vitro and little is known about the phenotypic characteristics in vivo, their 
anatomical localisation or their contribution to organogenesis [49]. In vivo characterisation 
of MSCs would be extremely promising in providing therapeutic manipulations of these 
stem cells.  
 
MSCs are most prevalent in the bone marrow where their frequency has been estimated to 
be around 1 in every 3.4 x 10
4
 cells [50]. Within the bone marrow MSCs are an important 
member of the HSC niche and help to generate the microenvironment necessary for the 
maintenance, proliferation and differentiation of HSCs [50]. The number, frequency and 
differentiation capacity of MSCs decreases with age within the bone marrow [51].  Whilst 
the bone marrow is the most highly populated location of MSCs, they have been found in 
most tissues, although the exact localizations of MSCs in vivo are still improperly 
understood. MSCs were classified according to the characteristics displayed by cultured 
cells.  However, when MSCs are cultured in vitro they may display markers that may not 
be displayed on the cell in vivo due to not being surrounded by all the extrinsic factors 
supplied by the physiological stem cell niche, and so it becomes difficult to establish the 
true identity of MSCs in their natural environments. Various methods have been used to 
try and establish which tissues MSCs reside in, including using stem cell markers known 
to be expressed on cells in vitro to look for the cells in vivo or infusing marked cultured 
stem cells in vivo and following their distribution[52].  Studies have found MSCs in 
adipose tissue [53], amniotic fluid [54] and dental pulp [55]. These findings are in 
agreement with results obtained by Young, H et al [56] which led them to conclude that 
progenitor and pluripotent stem cells are located in all organs having a connective tissue 
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compartment.  Another method used to determine the location of MSCs is to isolate tissues 
and evaluate each of them for the presence of MSCs. By simultaneously analysing 
different tissues and organs for their MSC contents, Da Silva Meirelles et al [52] found 
MSCs in the brain, spleen, kidney, lung, liver, bone marrow, muscle, thymus and pancreas 
and found that they each displayed similar morphology. The animals used in this study 
were perfused before the organs were removed, the blood was analysed for the presence of 
MSCs but none could be cultured indicating that MSCs are absent from the blood under 
normal physiological conditions. But whilst many studies have been unable to locate 
MSCs in the normal peripheral circulation [57],  some studies have been successful; 
Zvaifler et al. [58] found cells that expressed MSC marker CD105 and were capable of 
differentiating into adipocytes or osteoblasts under appropriate conditions in the peripheral 
blood. Also, Mansilla et al [59] found not only MSCs in the blood but also found that their 
numbers were increased in samples taken from patients who had suffered acute burns, 
indicating that they enter the circulation in response to injury.  
 
 In addition to being able to differentiate into various cell types, MSCs have been shown to 
provide cytokine and growth factor support for expansion of haematopoietic and 
embryonic stem cells [60]. MSCs express a range of cytokines including G-CSF, SCF, 
LIF, M-CSF, IL-6 and IL-11 [61] and the levels of expression of these cytokines is partly 
controlled by the environment around the stem cell niche and the actions of inflammatory 
stimuli (e.g. TNFα) acting on the MSCs themselves.  
 
 MSCs not only provide cytokine support the are also known to have immunomodulatory 
effects, MSCs are known to suppress the activation and proliferation of CD4+ and CD8+ 
lymphocytes in vitro [62], they have also been shown also to affect the function of antigen 
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presenting cells; MSCs reduce the expansion of dendritic cells (DC) and natural killer 
(NK) cells [63]. Those DCs that do form have a reduced potential, this was shown by 
Xiao-Xia Jiang et al [64] who found that DCs isolated from co-cultures with MSCs had a 
reduced potential to activate allogenic T cells. Conversely, MSCs cause an increase in the 
number of CD4+ CD25+ regulatory T cells [65].  Plumas J et al. [66] found that MSCs 
inhibited the proliferation of T cells in the presence of a number of different stimuli, and 
further discovered their mode of action was inducing the apoptosis of activated T cells 
whilst having no effect on resting T cells. MSCs have also been shown to significantly 
reduce the expression of activation markers CD25, CD38, and CD69 on the surface of 
stimulated lymphocytes [62] and  human MSCs have been shown exert their suppressive 
effects even when MSCs and lymphocytes are separated by a permeable membrane [67] 
suggesting that soluble factors may be involved. Further, soluble factors secreted by the 
MSCs have suppressive effects but the culture medium of MSCs has been shown to have 
no effect on lymphocytes unless the MSCs were co cultured with the lymphocytes. This 
indicates that the MSCs do not normally express the suppressive factors and therefore 
suggests that there is some kind of cross talk between the cells which causes the MSCs to 
become activated and secrete the soluble suppressants [68].  
MSCs are not immunogenic and do not stimulate alloreactivity, MSCs themselves do not 
activate T cells in their host or when transplanted into a recipient. This is because MSCs 
do not express co-stimulatory molecules e.g. CD40/CD40L and B7-1 or B7-2 [69] 
meaning that they cannot activate T cell responses. Further, MSCs  can escape lysis by 
cytotoxic T cells and NK cells making them ideal candidates for cellular therapy [70].  
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5.3. Therapeutic uses of MSCs and mechanisms of recruitment to tissue 
 
MSCs have potential uses within the field of transplant therapy, due to their ability to self 
renew and differentiate into a range of cell types, and because of their immunomodulatory 
effects. Many studies have been performed with MSCs to establish their therapeutic 
utilities. Following transplantation, allogenic MSCs have been detected in recipients at 
extended time points confirming their lack of immune recognition [60]. Because they don’t 
elicit an immune response, once harvested they can be infused into either autologous or 
allogenous hosts without rejection, meaning the recipient need not be given 
immunosuppression [69]. These properties have made MSCs ideal candidates for use in 
the prevention of rejection of solid organ or HSC transplants and of graft verses host 
disease  [71], as well as in the treatments of myocardial infarction [72] and ostegenesis 
imperfecta [73].    
 
Significant questions remain to be answered before MSCs can be used therapeutically to 
their best ability; what is the best method of delivery of these cells? How do they get to the 
sites of injury? And how do they exert their clinical effect? Firstly, MSCs have been used 
therapeutically by local administration of ex vivo expanded cells, but systemic 
administration of MSCs has proven to be more difficult because the number of MSCs that 
home to the site of the injury is very low [74]. Determining where MSCs migrate is a 
crucial step in developing MSC therapies and studies have shown that after systemic 
infusion there are very few MSCs in the bone marrow indicating that they home to other 
tissues or organs. It has also been shown, in rats, that a large proportion are trapped within 
the lungs and liver [75], but that administration of a vasodilator significantly altered where 
the MSCs migrated to by allowing them to escape capture from the lungs. Other models 
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[76], [77] have shown that there is very little or no trafficking of MSCs to sites of 
undamaged tissue, therefore showing that MSCs are selectively recruited to sites where 
therapeutic intervention is required [78]. Also, Langer et al [79]showed that induction of 
vascular injury in vivo resulted in increased recruitment of injected MSCs.  This suggests 
that MSC trafficking to sites of injury is part of the natural healing response and that 
administration of the patients own or donor MSCs to sites of injury can enhance the 
reparative response.  
 
Although the sites to which MSCs are recruited are now better established, the 
mechanisms by which MSCs are mobilized into the circulation, undergo recruitment and 
transmigrate across the endothelium are not yet fully understood. Leukocyte homing in 
response to inflammatory stimuli is well known and HSC recruitment has been suggested 
to occur via a mechanism similar to that of leukocytes. Looking at the mechanisms by 
which HSCs are recruited may give an idea of what mechanisms are involved in MSC 
recruitment. HSCs and leukocytes employ a large proportion of similar processes such as 
the use of L- and E- selectin during the initial capture and rolling stages.  But MSCs do not 
express L- selectin on their surface and the role of E-selectin is still to be determined [80]. 
Also, MSCs do not express platelet endothelial cell adhesion molecule (PECAM) which 
has a role in transmigration across the endothelial wall for leukocytes. Observations 
suggest that although MSCs may utilise a similar method if migration they must use a 
completely different set of adhesion molecules. Ruster et al [80] showed that MSCs bind to 
human umbilical vein endothelial cells (HUVEC) in a similar way to peripheral blood 
mononuclear cells and CD34+ cells, i.e. the rapid extension of podia, followed by rolling 
and firm adhesion. The binding of MSCs to the HUVECs was reduced when antibody 
against P-selectin was used to pre-treat the endothelial cells and increased when 
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endothelial cells were pretreated with TNFα. The same group also showed a reduced level 
of binding to vessel walls in P-selectin deficient mice  [80]. Since MSCs do not express 
the P-selectin ligand P-selectin glycoprotein ligand 1 (PSGL-1) they may express a novel 
ligand of their own.  
 
The actions of those cells that do migrate to sites of injury is another subject of contention 
but the most popular theory is that MSCs act to repair tissue injuries by the secretion of 
chemokines, cytokines and extracellular matrix proteins that alter the tissue 
microenvironment. These secreted factors inhibit fibrosis and apoptosis and promote 
angiogenesis and stimulate host progenitors to divide and differentiate into functional 
reactive units [81].  
 
5.4. Platelets as potential assistants in MSC recruitment 
At sites of disrupted endothelium, platelets are  be the first line of defence and adhere to 
the collagen in the sub endothelium where they prevent blood loss and initiate the healing 
process [79]. Platelets have been shown to aid in the ex vivo expansion of MSCs for use in 
therapies. Expansion of MSCs in vitro is necessary for their use in therapeutics where large 
quantities are required. Normally, fetal calf serum is used as a growth supplement for 
MSCs but if the MSCs are to be used clinically this is not possible as contact between 
MSCs and FCS must be kept to a minimum according to European legislation [82]. 
Platelets are known to secrete a number of cytokines and growth factors, and platelet 
lysates have been shown to be able to promote expansion of MSCs in in vitro culture [82]. 
Platelet lysates were shown to contain platelet derived growth factor (PDGF), basic 
fibroblast growth factor (bFGF), transforming growth factor (TGF-β) and insulin like 
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growth factor-1 (IGF-1) [82] as well as vascular endothelial growth factor (VEGF) and 
platelet derived epidermal growth factor (PDEGF). These factors are involved in 
chemotaxis and cellular proliferation [83]. 
 
At sites of injury or infection platelets can interact with neutrophils and monocytes as well 
as signal mast cells, macrophages and dendritic cells if they gain access to the 
extravascular space whilst also receiving signals from macrophages and mast cells in the 
form of platelet activating factor (PAF) showing that at sites of inflammation platelets can 
both supply and respond to signals [84].Activated platelets release proinflammatory 
mediators such as IL-1β and at sites of inflammation, circulating platelets adhere to the 
exposed subendothelial matrix and become activated, activated platelets are known to 
express P-selectin, a vascular cell adhesion molecule known to bind to P-selectin 
glycoprotein ligand 1 (PSGL-1) on circulating leukocytes. These interactions mediate 
rolling of leukocytes (Figure 5.2) followed firm adhesion, mediated by integrins and 
transmigration across the vessel wall [84] mediated by platelet endothelial cell adhesion 
molecule (PECAM). 
The importance of platelet interactions with endothelium and its contribution to 
inflammatory events was further shown by Gawaz et al  [85] who demonstrated that 
activated platelets modulate monocyte chemotactic protein-1 (MCP-1) secretion from the 
vessel wall and surface expression of intercellular adhesion molecule- 1 (ICAM-1) on the 
endothelium.  
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Figure 5.2. Recruitment of leukocytes from the circulation is mediated by platelet 
interactions.  
P selectin on platelets binds to p selectin glycoprotein ligands on Polymorphonuclear 
leukocytes (PMNs; neutrophils) instigating rolling. Firm adhesion of the cells and 
eventual transmigration through the vessel wall is mediated by integrins and PECAM 
respectively. [84]. 
 
 
 
 
 
 
There is a small but definite presence of HSCs in circulating blood which are thought to 
migrate to extramedullary sites, the trafficking of these HSCs is thought to have similar 
mechanisms to that of leukocytes [86]. Further, HSCs were shown to traffic constitutively 
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to multiple extramedullary tissues where they remain for approximately 2 days before they 
enter the draining lymphatics and return to the blood. HSCs express multiple traffic 
molecules including PSGL-1, VLA-4 and LFA-1 but the exact mechanisms by which 
HSCs are recruited from the blood to tissues remains to be known [86], although platelets 
have been shown to play a role in the adhesion of HSC to endothelium. Janowska- 
Wieczorek et al [87] showed that when HSCs are covered with platelet microparticles their 
adhesion to endothelium is increased as is the speed by which the engraftment occurs 
indicating that platelet microparticles are involved in both adhesion and homing of HSCs. 
It is thought HSCs may follow trafficking patterns similar to leukocytes when they are 
homing to the bone marrow, involving similar rolling, firm adhesion and transmigration 
events. Frenette et al [88] discovered that homing of HSCs is regulated primarily by P and 
E selectins and to a lesser extent vascular cell adhesion molecule (VCAM-1). It is unclear 
however which ligands on the HSCs bind to P or E selectin on the vasculature. Activated 
platelets have been shown to increase the migratory abilities of vascular smooth muscle 
cells and endothelial cells which are important in repair of vessel walls [89]. 
Whilst the interactions between platelets and leukocytes and platelets and HSCs have been 
investigated the interactions between platelets and MSCs have not.  Since platelets have 
clear roles in the trafficking and migration of leukocytes and HSCs and their progenitor 
cells, they may also be involved in the trafficking of MSCs. It may be possible that 
platelets recruit MSCs to sites of injury where they induce them to differentiate and 
participate in the restoration of damaged tissue.  
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5.5. Hypothesis 
The mechanisms by which MSC are recruited to sites of injury are not well defined. 
Recent studies show that platelet lysates help in the growth and differentiation of MSCs 
and others indicate that P-selectin may be involved in the process of capture of the MSCs 
and aid their rolling along the surface of endothelium. Since platelets express P-selectin 
when activated, we hypothesised that they may bind to MSCs in the peripheral blood 
circulation or to the wall of damaged vessels, and aid in recruitment of MSC to the vessel 
wall. 
 
5.6. Aims 
We aimed to determine if platelets bind to MSCs in whole blood and platelet rich plasma 
under normal conditions and upon the addition of the platelet activating agent TRAP. In 
parallel, we aimed to use flow based assays to determine if flowing MSCs in blood could 
bind to model capillaries coated with collagen (a platelet-binding surface) or purified P-
selectin.  
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6. Materials and Methods 
6.1. Methods  
Blood Collection 
Blood was collected from consenting adults into tubes containing either Citrate Phosphate 
Dextrose Adenine (CPDA; Sigma) at a ratio of 1:7 or the peptide thrombin-inhibitor 
PPACK (Sigma), at a concentration of 40µM and mixed.  Samples were used within 2h of 
withdrawal.  
 
Platelet Rich Plasma 
Platelet rich plasma (PRP) was made from whole blood by centrifuging at 200g for 
5minutes, after which the plasma layer was collected.  
 
Mesenchymal stem cell culture  
Mesenchymal stem cells were purchased (Lonza) at passage 2. The cells were thawed and 
seeded onto 75cm
3
 flasks (T75) which had been pre coated with fibronectin (1µg/ml). 
Cells were grown in Mesenchymal Stem Cell Basal Medium (MSCBM; Lonza) with 
additional Mesenchymal Cell Growth Supplement (MCGS), L-glutamine, and GA-1000 
antibiotic (Lonza) (Complete culture medium). Complete medium was renewed every 4 
days. Cells were grown at 37
o
C in 5% CO2. Cells were grown to ~ 90% confluence before 
being passaged. MSCs were removed from the surface of the flask to enable them to be 
passaged or used in an experiment, cells between passage 7 and 9 were used for 
experiments. The culture media was removed from the flask and the cells rinsed in 2ml 
EDTA (0.5mM; Sigma®) for 1-2 minutes to remove calcium and magnesium. The EDTA 
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was aspirated and cells were dissociated by the addition of 2ml of trypsin (1x; Sigma®) to 
the flask followed by incubation at 37
o
C/5% CO2 for 5-10minutes until the cells appeared 
round when viewed under the light microscope. The flask was then firmly tapped to fully 
dissociate the MSCs before 8ml complete culture medium was added. The medium plus 
MSCs was centrifuged at 300g for 5 minutes. The supernatant was then discarded and the 
cell pellet was resuspended in 1ml of complete culture medium. If cells were to be 
passaged, another 2ml of medium was added to the cells giving a total of 3ml. This was 
split into 3x 75cm
3
 flasks each containing 7ml of complete culture medium. For assays, 
cells were held in 1ml of medium and their concentration measured using a Nexcelom 
Cellometer cell counter (Biosciences); 20µl of MSCs was added to a Nexcelom slide and 
placed into the microscope reader.  The concentration was determined as cells/ml.  
 
Flow Cytometry to analyse platelet binding to MSC in blood or PRP  
MSCs were harvested and diluted to a standard concentration of 1x 10
6
/ml in complete 
culture medium.  When MSCs were to be analysed on their own, 100µl aliquots were 
added to polypropylene FACS tubes to be stained. When adding the MSCs to blood, they 
were mixed at a ratio of 1:9 in bijoux tubes containing a flea on a magnetic stirrer. 
Alternatively MSCs were added in the same ratio to PRP. Whole blood or PRP was stirred 
for either 5minutes or 15minutes before 100µl aliquots were removed and added to 
polypropylene FACS tubes to be stained.  In some cases, thrombin receptor activating 
peptide (TRAP; Tocris Biosciences) was added to the blood/PRP and MSC mix (20µM) 
before stirring commenced; 100µl aliquots were taken after 5 minutes sand 15 minutes and 
stained along side the other samples.  
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 Samples were stained with appropriate antibodies against antigens identifying MSC 
(CD105), platelets (CD42b) or leukocytes (CD45) (Table 2.1) for 30minutes in the dark at 
room temperature, after which 2ml FACS lyse (BD Biosciences) was added to each 
sample and left for 10minutes in the dark at room temperature. Samples were centrifuged 
at 300g for 5minutes at room temperature and supernatants were poured off, pellets were 
washed in 2ml phosphate buffered saline (PBS; Sigma) containing no Calcium or 
Magnesium plus 0.5% albumin (Sigma) (0.5%PBSA), centrifuged and supernatant poured 
off. Pellets were washed again in 0.5% PBSA- and pellets were finally resuspended in 
500µl of 2% formaldehyde in PBS.  Samples were read of on the FACS Cyan flow 
cytometer.  
Antibody Flourophore Concentration 
used 
Company 
CD105 FITC 1:200 Ancell 326-040 
CD42b PE-CY5 1:10 BD Pharmingen 551141 
CD45 FITC 1:100 ImmunoTools 21270453 
 
Table 6. 1. Antibodies used the fluorophores they were conjugated to and the 
concentrations they were used at. 
FACS analysis.  
Flow cytometry data was analysed by Summit v4.3 software. The forward scatter/side 
scatter plot was used to distinguish the MSC population which was gated around; the gate 
was applied to the subsequent plots when desired. Fluorescence intensity Plots used to 
analyse the data included CD105-FITC /CD42b-PE-Cy5 and FITC and PE-Cy5 alone. 
Using the CD105/CD42b plot, quadrants were used to determine CD105 positive and 
CD42b positive cells. The quadrants were set at 5.27 for CD105- FITC and 22.34 for 
CD42b- PE-Cy5; any cell falling within quadrants 1 and 2 was said to be PE-Cy5 (CD42b) 
positive and any cell falling within quadrants 2 and 4 was said to be FITC (CD105) 
positive, any cell falling with quadrant 2 was classed as being double positive. For 
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analysis; cells that fell with quadrant 2 were taken as a percentage of cells that fell within 
quadrants 2 and 4 combined.   
 
Flow-based Assay of MSC adhesion in flowing blood 
For the flow assay, MSCs were dissociated and stained with Cell Tracker Green 
(Invitrogen); 5µl was added to 10ml culture medium (5µM) with no added supplements 
and to which the MSCs were added and left to incubate at 37
o
C/5% CO2 for 30minutes. 
The cells were centrifuged at 300g for 5minutes and the medium removed, and the cells 
were resuspended in 10ml of complete culture medium and allowed to incubate for a 
further 30 minutes. Finally the cells were centrifuged, the supernatant was removed and 
the cells were resuspended in 1ml of medium for the concentration to be measured. The 
cells were diluted to a final volume of 1x 10
6
/ml and added to blood. 
Glass capillary slides (microslides) with rectangular cross section 3mm x 0.3mm and 
length 5mm were coated by drawing 50µl of the appropriate coating protein solution into 
the slide with a pipette followed by incubation at 37
o
C/ 5% CO2 for 1 hour. The slides 
were washed and remaining protein-binding sites were blocked with PBS containing 1% 
albumin for 2 hours at 37
o
C/5% CO2. Slides were coated in either P-selectin (10µg/ml; 
R&D systems) or type I collagen (500µg/ml; Horm collagen; Axis-Shield) or albumin 
alone.  
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Figure 6.1. Diagrammatic representation of the flow assay.  
Samples were pulled through the microslide by a syringe pump, the flow of MSCs were 
captured by video and displayed on the television for analysis.  
 
 
 
The flow assay is shown diagrammatically in figure 2.1. The coated microslide was placed 
under the microscope having been glued to a glass slide to hold it into place. Double sided 
sticky tape was wrapped around either end of the microslide and silicon rubber tubing was 
attached. One end was connected to a syringe pump (Harvard apparatus) and the other was 
connected to a valve which could be switched between reservoirs holding the test sample 
or PBS. Initially PBS without Ca or Mg was flushed through the system, and then the test 
sample was perfused for 5 minutes at a flow rate (0.181ml/min) chosen to provide a wall 
shear rate of 70s
-1
.  
 
37° C enclosure
Electronic valve
MSC in 
Blood
Wash 
reservoir
Microscope
Microslide
Syringe pump
Video recorder
TV for analysis
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The test sample was 2ml blood collected into either CPDA or PPACK for the flow assay, 
to which 200ul fluorescent-labelled MSCs were added MSCs flowing through the 
microslide were viewed by the fluorescence microscope equipped with a CCTV camera 
and images recorded with a video recorder. 
 
Flow assay analysis.  
Behaviour of mesenchymal stem cells was analysed by watching the video tape of the flow 
assay, examining recordings of approximately 30 seconds made at10 different fields along 
the centreline of the microslide for each condition. First, the video playback of a field was 
stopped and the number of MSCs in view on the screen was recorded; next a line was 
drawn down the middle of the screen and the number of MSCs flowing past that line in 1 
second was counted (Flux). Finally the time MSCs took to cross the screen of the 
television was recorded.  The size of the screen was measured using a microscope stage 
micrometer viewed by the CCTV camera.  From the above, the following were calculated: 
 
1. The number of cells in view was converted to the number of cells per mm
2
 at the wall of 
the microslide.  
2. The number of MSCs flowing past the line in 1 second (Flux) was converted to the 
percentage of total cells flowing past.  
3. The time it took MSCs to cross the screen was converted to velocity (µm/s).  
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7. Results 
7.1. Binding of platelets to MSC in stirred blood 
Firstly the antibody concentrations needed for the assay had to be determined. This was 
achieved by staining 100µl aliquots of MSCs with anti CD105-FITC antibody at differing 
concentrations; 1/50, 1/100 and 1/200 (Figure 7.1) and staining blood for platelets with 
anti CD42b-PE-Cy5 antibody at differing concentrations; 1/5, 1/10 and 1/20. MSCs were 
tested alone and mixed 1:10 in whole blood; blood was also tested alone without the 
additions of MSCs. Unstained samples were also tested Figure 7.1). These titration 
experiments showed that the concentration of anti CD105 antibody that was sufficient for 
use was 1/200 as the level of fluorescence at this concentration was the same as at a 
concentration of 1/50. The concentration of anti CD42b antibody that was sufficient for 
use was 1/10 because the level of fluorescence at this concentration was the same as that at 
1/5 but levels decreased when a concentration of 1/20 was used.  
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a)                                                                     b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
c)                                                                  d)    
 
 
 
 
 
 
 
        e)                                                                   f) 
 
 
 
 
 
 
 
Figure 7.1. MSCs stained with CD105-FITC at different concentrations. 
a) MSCs alone stained with CD105-FITC were gated around. 
b) The position of MSCs stained with CD105-FITC is shown on the FITC/PE-
Cy5 graph 
c) The position of unstained MSCs is shown on the FITC histogram. 
d) MSCs stained with CD105- FITC at 1/50 concentration. 
e) MSCs stained with CD105- FITC at 1/100 concentration. 
f) MSCs stained with CD105- FIITC at 1/200 concentration. 
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Next, MSCs were mixed with whole blood (CPDA) or PRP in bijoux tubes at a ratio of 
1:10 and stirred; 100µl samples were removed after 15minutes and stained with both 
CD105 and CD42b using the concentrations of antibodies determined  above. In a separate 
bijoux tube, TRAP a platelet activator was added to the blood/MSC mixture and again 
100µl samples were taken and stained for both CD105 and CD42b. MSC or blood samples 
alone were also stained for either CD105 or CD42b respectively, or left unstained.  With 
the scatter plots obtained from these samples it was possible to determine where the MSCs 
lie on the forward scatter/ side scatter plot when sampled alone and when mixed with 
whole blood. Further, it was possible to set boundaries to classify cells as being either 
positive or negative for CD42b and/or CD105 as illustrated in figure 7.2.  
 
Using the forward scatter/ side scatter plot the MSC population was determined by eye and 
gated around; this gate was applied to all subsequent plots including a CD105/CD42b plot 
and CD105 and CD42b histograms (Figure 7.2). Using the CD105(FITC)/CD42b(PE-Cy5) 
plot, quadrants were applied so that 99% of cells were within the quadrants defined as 
being negative when they were unstained and in quadrants defined as being positive when 
stained.  The percentage of cells in each of the resulting quadrants was used to determine 
how many cells were CD105 positive and CD42b positive; cells within quadrants R2 and 
R3 were classed as being CD42b positive, i.e. platelets. Cells within quadrants R3 and R5 
were classed as CD105 positive, i.e. MSCs, those cells with R3 were said to be double 
positive i.e. MSCs with platelets bound, and those cells within quadrant R1 as being 
double negative, i.e. neither MSCs nor platelets. The number of MSCs that were double 
positive was worked out as being the number of cells within R3 as a percentage of cells 
within R3+ R5.  
737539 
 
77 
 
a)              b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)                                                                            d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. FACS plots of MSCs.  
a) Forward scatter/side scatter plot for MSCs alone. MSC population is gated. 
b) Forward scatter/side scatter plot for MSCs in whole blood. MSC population is 
gated. 
c) CD105/CD42b plot of unstained MSCs. 
d) CD105/CD42b plot of MSCs stained with CD105- FITC and CD42b- PE-Cy5. 
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Using the boundaries described, results for the experiment also described above showed 
that MSCs mixed with blood gave a similar number of double positive cells (4.1%) as 
MSCs with PRP (4.6%), whilst the addition of platelet activator TRAP reduced the 
number of double positive cells in whole blood to 1.5%.  MSCs alone gave a background 
level of CD42b staining of 0.5%.  
 
Following this, experiments were conducted with varying conditions to identify 
differences in MSC and platelet binding between the conditions. The effects of 
anticoagulant used were tested by stirring MSCs with blood that was collected into either 
CPDA a calcium chelator which prevents the coagulation cascade from occurring, or 
PPACK a thrombin inhibitor. The effects of time were tested by stirring blood and MSC 
mixtures for either 5 minutes or 15 minutes and the effect of platelet activation was tested 
by adding TRAP to the blood and MSC mixture. MSCs were also mixed with PRP instead 
of whole blood in some experiments. The percentage of cells that were double positive for 
CD105 and CD42b were calculated as above and the averages of the data retrieved were 
used to compare the different conditions ; standard error of the mean (SEM) was also 
calculated and error bars added to the graph (Figure 7.3).  
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Figure 7.3.  Percentage double-positive particles when MSCs were mixed with 
either CPDA or PPACK blood or PRP for 5 minutes or 15 minutes, +/- TRAP.  
 Data are the mean +/- SEM from (n) experiments. Number in brackets above the bars 
indicates the number of repeats performed for that condition. * Indicates a significant 
difference (<0.05) in a paired T test in samples with/without TRAP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The average percentages show that overall there is a greater number of CD105 and CD42b 
double positive cells within the MSC gate when they are mixed with PPACK blood than 
with CPDA blood with e.g. 13.2% in the PPACK blood after 5 minutes compared to 6.7% 
in CPDA blood after 5 minutes. But an unpaired T test showed that there was no 
significance between these results. The results also show that time has only a slight effect 
on the binding of platelets to MSCs, with the number increasing slightly between 5 to 15 
min for most conditions except in PPACK blood, not surprisingly, changes in time do not 
* 
* 
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produce significant results in unpaired T tests. Surprisingly, the addition of TRAP to the 
blood and MSC mixtures to activate platelets reduced the levels of CD105/CD42b double-
positive cells in both CPDA and PPACK blood to 2.5% and 3.1% respectively after 5 
minutes. The difference in the percentages of double positive cells between CPDA blood 
after 5 minutes and CPDA blood plus TRAP after 5 minutes were significant when using a 
paired T test to analyse the results with a p value of 0.0185. There was also a significant 
difference after 15 minutes in CPDA blood between samples that had not had TRAP added 
and those that did (p= 0.0244). The differences in PPACK blood before and after addition 
of TRAP were not significant, possibly because of the large standard error bars. The 
results also illustrate that mixing MSCs with blood provides more double positive cells 
than MSCs mixed with PRP, although upon the addition of TRAP to PRP the levels of 
binding between MSCs and platelets decreased, showing the same pattern as in whole 
blood. The average levels of background fluorescence (Figure 7.4) were low, at less than 
1% showing that the levels of fluorescence obtained from samples were true readings. 
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Figure 7.4. Percentage background fluorescence when MSCs were mixed with 
either CPDA or PPACK blood or PRP for 5 minutes or 15 minutes and were left 
unstained. 
The level of background fluorescence in unstained samples was less than 1% in most 
samples.  
 
 
 
 
 
We checked whether any cells within the MSC gate were in fact leukocytes, e.g. 
aggregated with platelets. Samples (using CPDA blood alone) were stained with CD45-
FITC, a leukocyte marker. The FACS data were analysed as for staining with CD105 and 
the results  illustrated that there were very few cells within the MSC gate that were 
positive for CD45, with stained samples having no more fluorescence than unstained 
samples, indicating that platelets within this gate were not binding to leukocytes (Figure 
7.5) 
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Figure 7.5. The percentage of cells within the MSC gate that are positive for CD45.  
The number of CD45 positive cells within the MSC gate is no larger in stained samples 
than in unstained samples showing that there are no CD45 positive cells within this gate.  
US= unstained.  
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Figure 7.6 Effect of anticoagulant and adhesive substrate on the number of MSCs 
per mm
2
. 
The number of MSCs in view on the screen was converted into number of MSCs per 
mm
2
.There was little difference in the number of cells per mm
2
 between samples of 
MSCs in CPDA or PPACK blood when flowed over surfaces of albumin, collagen or P 
selectin.  
7.2. Behaviour of MSC perfused across adhesive surfaces in blood. 
The MSCs were stained with cell tracker green to enable them to be viewed under a 
fluorescent microscope; they were then added to either CPDA or PPACK blood at a ration 
of 1:10. Samples were then flowed through microslides coated in albumin, collagen or P 
selectin and recorded onto video tape. The video tape were analysed to obtain  the number 
of cells near the wall per mm
2
, the flux of the cells near the wall as a percentage of the 
total perfused, and the velocity of the cells in µm/second. Averages were compared for 
CPDA vs. PPACK as anticoagulants, and for surfaces coated with albumin vs. collagen vs. 
P selectin, standard error bars were also added to graphs.  
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Figure 7.7 Effect of anticoagulant and adhesive substrate on percentage of cells 
flowing past per second. 
The number of cells flowing past an arbitrary line per second was converted into the 
percentage of the total cells flowing past according to the flow rate used for the assay. 
There was very little difference in flux between samples of MSCs in CPDA or PPACK 
blood when flowed over surfaces of albumin, collagen or P selectin. 
Figure 7.6 shows that there was little difference in the numbers of MSCs in view between 
the different proteins used to coat the microslides and between the anticoagulant used in 
the blood. Two way ANOVA revealed there were no significant effects of anticoagulant or 
surface on the number of MSCs in view. 
 
The number of cells flowing past an arbitrary line on the screen (flux) in 1 second was 
counted, and converted into the percentage of the total number of cells perfused. Averages 
of the resulting percentages were used; the resulting figures were plotted onto graphs 
comparing CPDA to PPACK and albumin to collagen and P selectin (Figure 7.7). 
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Figure 7.8. Effect of anticoagulant and adhesive substrate on the velocity of MSCs 
flowing through microslides. 
The time it took MSCs to cross the screen was converted to velocity. There was very 
little difference in velocity between samples of MSCs in CPDA or PPACK blood when 
flowed over surfaces of albumin, collagen or P selectin. 
 
The differences in flux between the types of surface and the anticoagulants used are very 
small. There were a slightly larger percentage of cells flowing close to the walls in 
microslides coated with collagen and P selectin than albumin but the error bars for all 
conditions were also quite large, and there was very little difference between the use of 
CPDA or PPACK. None of the differences were significant when ANOVA was used to 
analyse them.  
 
The time it took for MSCs to cross the screen was converted into velocity; averages of the 
10 fields viewed per condition were used to compare the samples. The figures obtained 
were plotted onto graphs comparing CPDA to PPACK and albumin to collagen and P 
selectin again (Figure 7.8).  
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Again the differences between the samples are small but the biggest differences are 
between CPDA and PPACK blood on a P selectin surface with PPACK having a lower 
velocity than CPDA. Two way ANOVA showed no significance between the results.  
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8. Discussion 
8.1. Binding of platelets to MSC in stirred blood. 
Experiments performed have shown that a small proportion of platelets within the blood 
can bind to mesenchymal stem cells, under the right conditions. Cultured mesenchymal 
stem cells were harvested and stirred with whole blood, collected into either CPDA or 
PPACK anticoagulants, or stirred into platelet rich plasma (PRP). Samples were stirred for 
5 or 15 minutes before being stained with MSC marker CD105 and platelet marker CD42b 
and being analysed by flow cytometry. The effect of platelet activation was tested by the 
addition of TRAP, a platelet activating peptide, in some of the samples tested. Multiple 
repeats of experimental conditions were performed and the average results obtained were 
used to compare the effects of anticoagulant, time and platelet activation.  
 
The type of anticoagulant used seemed to have a small effect on the levels of double 
positive cells in samples, with MSCs mixed with PPACK blood having higher levels of 
platelet/MSC aggregates compared to CPDA blood after both 5 minutes and 15 minutes. 
Although the results obtained from CPDA blood were much more consistent with lower 
standard errors in CPDA blood than PPACK blood. The length of time that MSCs were 
mixed with blood had differential effects depending on which anticoagulant the blood was 
collected into, with the amount of double positive cells increasing after 15 minutes in 
CPDA blood but decreasing after 15 minutes in PPACK blood showing that more repeats 
are needed to fully determine the effects of time.  
 
Thrombin receptor activating peptide, TRAP is a synthetic peptide which mimics many of 
the effects of thrombin [90], it has been shown to stimulate platelet activation as well as 
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induce aggregation, ATP release and phospholipase C activity [90]. The experiments have 
shown that this peptide has a large effect on the binding of platelets to MSCs with the 
levels reduced upon addition of TRAP to the MSC/ blood mixtures. This may be because 
as the platelets are activated they either form platelet aggregates or bind to lymphocytes 
and leukocytes rather than to MSC. On this assumption, when MSCs were mixed with 
PRP which contains fewer leukocytes than whole blood, the levels of binding within the 
MSC gate would be expected to increase after the addition of TRAP because the platelets 
would have fewer leukocytes to bind to outside of the MSC gate. This was not the case; 
the levels of binding when MSCs were mixed with PRP were lower than in whole blood 
before the addition of TRAP, and in samples to which TRAP was added the levels of 
binding were decreased like they were in whole blood samples. To ascertain if platelets 
were binding to leukocytes within the MSC gate the levels of leukocytes present on the 
MSC gate was determined by staining samples with CD45 a leukocyte marker. The 
resulting FACS data revealed that there was no more fluorescence in samples stained with 
CD45-FITC than those left unstained illustrating that leukocytes are absent from the MSC 
gate. This therefore showed that within the MSC gate platelets are binding to MSCs or 
have formed platelet aggregates that are of similar size to MSCs.  
 
The above data has demonstrated that small levels of platelets are able to bind MSCs under 
appropriate conditions but that activated platelets are less likely to bind to MSCs. Since 
platelets are activated in response to injury or inflammation which is the time when MSCs 
are most prominent in the blood the results would suggest that platelets do not aid 
recruitment of MSCs in response to injury.  
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Future work 
Given the large error bars for some conditions, it would be desirable to carry our more 
repeats of each condition to fully determine effects of anticoagulant, time and activation. 
  
8.2. Behaviour of MSC perfused across adhesive surfaces in blood. 
MSCs were also analysed using a flow based system which simulates the flow of blood 
within vessels. MSCs were stained with cell tracker green and were mixed with whole 
blood collected into CPDA or PPACK anticoagulants. Samples were flowed through 
microslides coated with albumin as a control, or collagen or P selectin. Collagen was 
chosen because it is exposed upon injury to blood vessel walls and P selectin was used 
because previous studies have indicated that it aids in the recruitment of MSCs [80].  The 
flow of MSCs in blood was recorded on video tape which was used for analysis to 
determine if there were any differences between the surfaces and which anticoagulant the 
blood was collected into. Per condition i.e. PPACK or CPDA and albumin, collagen or P 
selectin 10 frames were viewed, in each of these frames the number of cells in view at the 
start was counted, the area in view was also determined and from this the number of cells 
per mm
2
 was deducted. There was little difference between the averages between the 
different conditions and two way ANOVA revealed no significance between the different 
conditions. Also calculated from the video recording was the flux of the cells, this was 
calculated from the number of cells that crossed the screen in 1 second which was 
converted to a percentage of the total number of cells flowing through the microslide as the 
cells that were in view were cells that were near the microslide wall and not the total 
number of cells flowing through. The average results obtained from 5 experiments for each 
condition were used to compare the conditions. The highest percentage was from CPDA 
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blood flowed over a collagen surface and was 33.21% of the total cells, the lowest 
percentage was from PPACK blood flowed over albumin which gave a percentage of 
26.43%. The difference between the highest and lowest percentages shows that the range 
between the condition types is narrow and analysis of these results showed that there were 
no significant differences between the conditions. The velocity of the MSCs was also 
calculated from the video tapes by counting how long it took for cells to cross the screen. 
Those MSCs that may have been adhering to the surface would have had a lower velocity 
(µm/s) than those that were not, also it would be expected that the velocity of cells flowing 
through microtubes coated in collagen or P selectin would be lower than albumin which 
was a control that MSCs are not expected to adhere to. But the velocity of cells in CPDA 
blood was quicker when flowed over collagen and P selectin than albumin which shows no 
adhesion between MSCs and the surfaces. The velocity of MSCs in PPACK blood was 
similar between albumin and collagen but was reduced when flowed over P selectin, but 
like the results obtained for the other parameters the range between the averages of the 
different conditions is small. Also, like the other parameters used to analyse the results, the 
two way ANOVA revealed no significance in the results.  
 
The results obtained from the flow assay suggest that MSCs do not adhere to collagen or P 
selectin.  The latter does not agree with the findings of Ruster et al. who found that binding 
of MSCs to HUVECs was reduced when antibody against P selectin was used.  Those 
studies were carried out using isolated MSC whereas this study used MSC suspended in 
blood, which is closer to the situation in vivo. 
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Future Work  
The flow assays were performed 5 times over collagen and P selectin but only 4 times over 
albumin so would need to be repeated many more times to confirm that MSCs do not bind 
to either of them. It would be interesting to determine if platelet activation had an effect in 
this experimental setting by the addition of TRAP to the samples before they are flowed 
over the microtubes. It may also be worth coating the microslide with different molecules, 
for example E selectin or VCAM-1 to ascertain is they are able to support binding of 
MSCs.  
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9. Appendix 
Primer sequences used for PCR 
 Primer Sequence Restriction site Length of product 
Amigo1 
forward 
5’GATCGAATTC|ATG|CA 
CCCCCACCGTGACCCG 3’ 
EcoR1 1476bp 
Amigo1 
reverse 
3’AGACTATGCGGGTAA 
CACCACGAGCTCCTAG 5’ 
Xho1 1476bp 
Amigo2 
forward 
5’GATCGGATCC|ATG|TC 
GTTACGTGTACACACT 3’ 
BamH1 1569bp 
Amigo2 
reverse 
3’ TGTGGAAAACACCGC 
AGGTGAGAGCTCCTAG 5’ 
Xho1 1569bp 
Amigo3 
forward 
5’GATCGGATCC|ATG|AC 
CTGGTTGGTGCTGCTG 3’ 
BamH1 1509bp 
Amigo3 
reverse 
3’AGGCTCCCAGGGTAC 
TGTTGGGAGCTCCTAG 5’ 
Xho1 1509bp 
Lingo1 forward 5’GATCGGATCC|ATG|CA 
GGTGAGCAAGAGGATG 3’ 
BamH1  
Lingo1 reverse 3’ TTCAAGTTGTACTTC 
TACTATGAGCTCCTAG 5’ 
Xho1  
NgR forward 5’GATCGAATTC|ATG|AA 
GAGGGCGTCCGCTGGA 3’ 
EcoR1 1461bp 
NgR reverse 3’TGTCACGAACCCGGG 
ACGACTGAGCTCCTAG 5’ 
Xho1 1461bp 
p75 forward 5’GATCGAATTC|ATG|GGG EcoR1 1323bp 
737539 
 
93 
 
 
 
Restriction sites that were incorporated into the primers are highlighted in red, start codons 
are boxed and stop codons are underlined.  
 
Internal primer sequences used for DNA sequencing  
 
Name Primer sequence 
hAmigo1 int 1 5’ATGGCCCAGCTGCAGAAA 3’ 
 
hAmigo1 int 2 5’AACGGGTGCTAGATGAGG 3’ 
hAmigo2 int 1 5’TATGTTGGAAGGTTCAAG  3’ 
 
hAmigo2 int 2 5’GAAAGCCCTCGTTTTGAG 3’ 
 
hAmigo2 int 1-2 5’ TATGTTGGAAGGTTCAAG 3’  
 
hAmigo3 int 1 5’ACGAGCATGCCTTCCACG 3’  
 
hAmigo3 int 2 5’ATAGGCAACGTACAGGAG 3’ 
 
hNgR int 1 5’ATGACACCTTCCGCGACC 3’ 
hNgR int 2 5’TTACCATCCCATCTGGAC 3’ 
 
hp75 int 1 5’TGTGCGAGGACACCGAGC 3’  
 
hp75 int 2 5’AGAAAAACTCCACAGCGA 3’  
 
 
 
 
 
 
 
 
 
 
 
GCAGGTGCCACCGGC 3’ 
p75 reverse 
 
3’TGACGGTGTAGGGGCC 
ACACTGAGCTCCTAG 5’ 
Xho1 1323bp 
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Primer sequences used for overlap extension PCR 
 
 
hAM1HA OLF 5’ GATGTTCCAGATTATGCTGGCCGAGCCGTGGTT 
AGC 3’ 
 
hAM1HA OLR 5’ GCTAACCACGGCTCGGCCAGCATAATCTGGAAC 
ATC 3’ 
hAM1 rev 5’ GATCCTCGAGTCACACCACAATGGGCGTATC 
AGA 3’ 
hAM2HA OLF 5’ GATGTTCCAGATTATGCTGTGTGCCCCACCGCT 
TGC 3’ 
 
hAM2HA OLR 5’ GCAAGCGGTGGGGCACACAGCATAATCTGGAAC 
ATC 3’ 
hAM2 rev 5’ GATCCTCGAGTTAAGTGGACGCCACAAAAGG 
TGT 3’ 
hAM3HA OLF 5’ GATGTTCCAGATTATGCTACCCCGGACTCCGAG 
GGT 3’ 
 
hAM3HA OLR 5’ ACCCTCGGAGTCCGGGGTAGCATAATCTGGAAC 
ATC 3’ 
hAM2 rev 5’ GATCCTCGAGCTAGGTTGTCATGGGACCCTC 
GGA 3’ 
hNgRHA OLF 5’ GATGTTCCAGATTATGCTTGCCCAGGTGCCTGC 
GTA 3’ 
 
hNgRHA OLR 5’ TACGCAGGCACCTGGGCAAGCATAATCTGGAAC 
ATC 3’ 
 
hp75HA OLF 5’ GATGTTCCAGATTATGCTAAGGAGGCATGCCCC 
ACA 3’ 
 
hp75HA OLR 5’ TGTGGGGCATGCCTCCTTAGCATAATCTGGAAC 
ATC 3’ 
 
HAEco FOR 5’ GATCGAATTCATGTCTGCACTTCTGATCCTA 3’ 
 
HABamHI FOR 5’ GATCGGATCCATGTCTGCACTTCTGATCCTA 3’ 
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